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INTRODUCTION 
Since the first working human genome draft was published in 2001, there has 
been rapid development of high-throughput sequencing technologies. The 
resultant mass of genomic datasets contains information about inter-individual 
genome variance of great interest for personalized medicine, which has become 
a major focus of human genomics, with the goal of providing comprehensive and 
reliable data regarding complex genetic phenotypes and, ultimately, imple-
menting this knowledge into clinical practice such that individuals’ genomic data 
can be used to assess individualized risk, including expected drug responsivity. 
Pharmacogenetics/genomics – the practice of administering treatments based on 
the individual’s genomic make-up – has started to become integrated into every-
day clinical practice, informing treatment decisions and allowing for more 
accurate and efficient selection of therapies that are best suited for specific 
patients. 
The extensively researched enzyme thiopurine methyltransferase (TPMT) is 
a notable example in personalized cancer and immunotherapy. TPMT is a cyto-
solic enzyme that catalyzes the S-methylation of aromatic and heterocyclic sulf-
hydryl compounds, including thiopurine drugs such as 6-mecaptopurine (6-MP), 
azathioprine (AZA), and 6-thioguanine (6-TG). These drugs are used to treat 
acute lymphoblastic leukemia (ALL) and autoimmune diseases as well as to 
prevent rejection of transplanted organs. Individuals with low or deficient TPMT 
activity are at risk of developing severe reactions to drugs methylated by TPMT. 
TPMT activity level correlates inversely with the accumulation of cytotoxic 
metabolites (6-thioguanine nucleotides), such that low enzyme activity results 
in high metabolite levels and vice versa. It has been shown in population studies 
that TPMT activity is trimodally distributed, with the three dominant modes 
observed being deficient/low, intermediate, and normal. Among people of Euro-
pean descent, approximately 0.3%, 11%, and 89% have deficient/low, inter-
mediate, and normal TPMT activity, respectively, indicating that some 11% of 
individuals in this population may be prone to adverse drug events. A small 
subgroup of individuals with ultra-high TPMT activity has also been described. 
One study showed a relationship between trinucleotide repeats in the TPMT 
promoter region and ultra-high TPMT activity.  
Several TPMT polymorphisms and mutations have been identified that alter 
(usually decrease) the encoded enzyme’s activity. Insufficient metabolism of 
standard-dosage thiopurine drugs by TPMT results in myelosuppression, a severe 
adverse event wherein bone marrow does not produce sufficient blood cells. 
Meanwhile, standard thiopurine doses are ineffective in patients with ultra-high 
TPMT activity because the drugs are eliminated rapidly. Aside from identifiable 
inactivating variants of TPMT, there are additional geno- and phenotype 
variances, especially among individuals with intermediate TPMT activity, 
indicating that there are factors other than TPMT genotype influencing TPMT 
activity.  
11 
In the first phase of this study, we determined TPMT activity in 253 healthy 
Estonian subjects, sequenced TPMT’s coding region, and determined the allele 
frequencies of TPMT genetic markers in the population. Previously undescribed 
mutations were detected. Next, we examined genotype-phenotype variance. The 
second phase of the TPMT study was conducted with a large cohort of 
randomly selected individuals from the Estonian Genome Center. The effect of 
S-adenosyl-methionine (SAM) on TPMT activity was studied. In addition, a 
genome-wide association study (GWAS) and meta-analysis were performed 
with an Estonian cohort, German pediatric ALL patients, and liver samples with 
the aim of finding new genetic markers of TPMT activity.  
  
12 
1. REVIEW OF THE LITERATURE 
1.1. The main aspects of pharmacogenetics/-genomics 
It has long been known that individuals respond differently to drugs due to many 
factors such as age, gender, liver and kidney function, environmental/ lifestyle 
factors, and drug-drug and drug-disease interactions. It has since become very 
clear that one’s genetic profile can have a big impact on drug sensitivity and 
efficacy (Meyer, 2004; Meyer, 2012). 
Pharmacogenetics was defined over half a century ago as the study of 
variable drug responses due to inherited characteristics (Vogel, 1959). Owing to 
the rapid development of genomics, molecular pharmacology, and genome 
analysis methods, we are now heading towards a situation where every patient 
will get prescribed a dosage according to their genetic make-up, thereby reducing 
adverse drug reactions (ADRs) and increasing the treatment efficiency (Johnson, 
2003; Meyer, 2012; Squassina et al., 2010; Weinshilboum and Wang, 2004). 
Frequently, the terms pharmacogenetics and -genomics are used interchan-
geably. However, in pharmacogenetic studies, particular candidate genes are 
investigated, whereas in pharmacogenomics (PGx) studies, the whole genome is 
scanned at the level of DNA and/or RNA. PGx studies may include various  
“-omics” methods, such as metabolomics, proteomics, and epigenomics, among 
others (Pinto and Dolan, 2011).  
There are two fundamental areas of PGx research, namely studies of the 
genetic underpinnings of pharmacokinetics (PK) and pharmacodynamics (PD) 
(Fig. 1). PK describes the course of drug and metabolite levels and the rate of 
drug metabolism in different tissues. It incorporates data describing drug 
absorption, distribution, metabolism, and elimination, which are referred to in 
conglomerate by the acronym ADME. PD describes the pharmacological effects 
of a drug on the body, desired or not. Thus, PD can be viewed as what the drug 
does to the body, whereas PK is what the body does to a drug. Variance in both 
mechanisms leads to differences in drug efficacy and toxicity (Johnson, 2003; 
Schwarz et al., 2016). 
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Figure 1. Pharmacogenetics/-genomics is comprised of different components underlying 
the mechanisms of drug actions. See the text for more details. Figure adapted from 
(Johnson, 2003). 
 
 
1.1.1. Drug metabolizing enzymes 
The biotransformation, metabolism, and/or detoxification of xenobiotics (i.e., 
exogenous compounds), including drugs, are mediated largely by enzymes known 
as xenobiotic metabolizing enzymes or drug metabolizing enzymes (DMEs). 
Once in the body, xenobiotics can affect a great variety of processes, including 
cell differentiation, cell division, apoptosis, and necrosis. The body manages 
xenobiotic effects with diverse phase I and phase II DMEs expressed in various 
tissues (Fig. 2); DMEs may be present in abundance basally or upregulated after 
exposure (Pasipoularides, 2016; Rushmore and Kong, 2002). The ultimate goal 
of the reactions mediated by these enzymes is to convert lipophilic drugs into 
hydrophilic metabolites amenable to excretion (Brunton et al., 2005; Schwarz et 
al., 2016).  
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Figure 2. Phase I and phase II enzymes. The relative size of each sector represents how 
much the indicated enzyme type contributes to drug metabolism. Those enzymes, were 
polymorphisms are known to affect drug efficacy are separated from the corresponding 
pie charts. Abbreviations: ADH, alcohol dehydrogenase; ALDH, aldehyde dehydro-
genase; CYP, cytochrome P450; DPD, dihydropyrimidine dehydrogenase; NQO1, 
NADPH:quinone oxidoreductase or DT diaphorase; COMT, catechol O-methyltrans-
ferase; GST, glutathione S-transferase; HMT, histamine methyltransferase; NAT, N-
acetyltransferase; STs, sulfotransferases; TPMT, thiopurine methyltransferase; UGTs, 
uridine 59-triphosphate glucuronosyltransferases. Figure adapted from (Evans and 
Relling, 1999). 
 
 
The phase I enzyme group includes mostly cytochrome P450 (CYP450) family 
enzymes. Generally, they modify the functional groups of xenobiotics/pro-
drugs, converting them into active compounds. In some cases, Phase I enzymes 
may inactivate drugs. Subsequently, drug detoxification is carried out by Phase 
II enzymes (e.g. methyl-, sulfotransferases, quinone oxidoreductases, N-acetyl-
transferases). Phase II enzymes alter chemical structures by adding groups that 
make compounds easier to excrete in urine (Evans and Relling, 1999; Schwarz 
et al., 2016). 
The Clinical Pharmacogenetics Implementation Consortium (CPIC) estab-
lished consensus terms for phenotyping individuals according to the activity of 
drug metabolizing enzymes (e.g. CYP2C19, CYP2D6, CYP3A5, CYP2C9, 
TPMT, DPYD, UGT1A1). Patients are classified as poor, intermediate, normal, 
rapid, or ultra-rapid metabolizers of a target drug. This diversity in metabolism 
is related mainly to the polymorphic genes encoding phase I and II DMEs. 
Polymorphism of DME genes may be the result of gene copy number variations 
(e.g. gene deletions and duplications), small insertions/deletions (indels), and 
single nucleotide polymorphisms (SNPs). Non- and hypofunctional alleles yield 
reduced drug metabolism and thus elevated risk for ADRs (Ingelman-Sundberg 
et al., 1999; Norton, 2001; Schwarz et al., 2016; Zhou et al., 2008); patients with 
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two such alleles for the same key gene should be administered lower doses. 
Intermediate metabolizers, who have one normal allele and one non-or hypo-
functional allele, may also suffer ADRs to standard doses. Standard doses of the 
drugs are suitable and expected to be therapeutically effective in patients with 
normal enzyme activity (usually two wild-type alleles). Conversely, the problem 
of faster than normal drug metabolism, due to the presence of one (rapid 
metabolism) or two (ultra-rapid metabolism) alleles is critical for drug efficacy. 
Such patients require higher doses to achieve drug efficacy because the drug is 
eliminated quickly (Ahmed et al., 2016; Caudle et al., 2016; Kirchheiner and 
Seeringer, 2007; Schwarz et al., 2016).  
In the case of genes that encode enzymes that activate pro-drugs, the opposite 
pattern occurs, wherein individuals with poor and intermediate enzyme activity 
may not reach therapeutic efficacy, while rapid and ultra-rapid metabolizers are 
at risk of ADRs due to excessive concentrations of active metabolites being 
produced. For example, the cytochrome P450 family isoenzyme CYP2D6 is the 
main metabolizer of codeine and tamoxifen, from which it produces morphine 
and endoxifen, respectively. Low CYP2D6 activity is due to loss of function 
alleles, whereas rapid/ultra-rapid CYP2D6 activity has been attributed to 
duplication of the functional gene. There have been several reported cases of 
routinely recommended codeine doses being lethal. For example, there was a 
case reported of a fatal opioid overdose in a breastfeeding neonate due to the 
mother who was taking codeine being a rapid metabolizer of CYP2D6 and, there-
fore, having excessive accumulation of morphine. Postmortem examination of 
the infant revealed significantly elevated serum morphine concentrations (Ahmed 
et al., 2016; Madadi et al., 2007). 
 
 
1.1.2. Drug transporters 
Translocation of drugs across biological membranes was long assumed to be 
mediated by passive transport. However, it is now very clear that the main 
critical modulators of drug absorption, tissue distribution, and elimination are 
transporters mainly in the intestines, liver, kidney, and blood-brain barrier. Two 
types of transporters have been discovered (Fig. 3): uptake and efflux.  
Uptake transporters facilitate drug translocation into the cells. Their driving 
force is mainly the exchange or cotransport of ions (e.g. Na+, H+). Notable 
examples of uptake transporters include several solute carrier (SLC) super-
family members, namely organic anion transporting polypeptides, organic anion 
transporters, and organic cation transporters (DeGorter et al., 2012).  
By contrast, efflux transporters expel compounds from the intracellular space 
into the extracellular milieu, thereby preventing the cellular accumulation of their 
substrates. Their driving force is ATP hydrolysis, which enables them to pump 
their substrates against steep concentration gradients. Efflux transporters include 
ATP-binding cassette (ABC) superfamily members, such as multidrug resistance-
related proteins, and multidrug resistance proteins (DeGorter et al., 2012).  
16 
 
 
Figure 3. Expression of drug transporters in (a) human intestinal epithelia, (b) kidney 
proximal tubule epithelia, (c) hepatocytes, and (d) brain capillary endothelial cells. 
Transporters with major roles in drug efficacy or toxicity are colored red. Sodium-
dependent taurocholate co-transporting polypeptide (NTCP), apical sodium-dependent 
bile acid cotransporter (ASBT), and bile-salt export pump (BSEP) are bile acid 
transporters. Peptide transporter 1 and 2 (PEPT1 and PEPT2) are transport small peptide 
fragments. Organic cation/carnitine transporter 1 and 2 (OCTN1 and OCTN2) transport 
organic cations and carnitine. Abbreviations: BCRP, breast cancer resistance protein; 
MATE, multidrug and toxin extrusion; MRP, multidrug resistance-associated protein; 
OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, 
organic cation transporter; PEPT, peptide transporter; P-gp, P-glycoprotein. Figure 
adapted from (DeGorter et al., 2012).  
 
 
Interindividual variability in activity among transporters is determined by several 
factors, including polymorphisms in drug transporter genes. A well-known 
example of transporter gene polymorphism effect is the case of the transporter 
gene SLCO1B1, which encodes the solute carrier organic anion transporter 1B1 
(OATP1B1). SLCO1B1 has a causative SNP (rs4149056) that reduces hepatic 
transport and increases plasma concentrations of simvastatins, resulting in myo-
pathy (Link et al., 2008). Several clinically impactful SLC and ABC transporter 
polymorphisms have also been described (Ahmed et al., 2016; Cascorbi, 2011; 
Chinn and Kroetz, 2007; Sissung et al., 2010; Srimaroeng et al., 2008; Yee et 
al., 2010; Zhou et al., 2016).  
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1.1.3. Drug targets 
Although studies of drug metabolism pharmacogenetics have been underway 
since the 1950s, the literature on drug target pharmacogenetics is much more 
recent, having emerged in the mid-1990s. Drug targets in the body can be direct 
or indirect. Direct drug targets may be receptors (nuclear or cell surface), 
enzymes, metabolites, ion channels, or transport proteins (Fig. 4). Indirect 
targets include proteins involved in the pharmacologic response, such as signal 
transduction proteins, downstream proteins, and proteins associated with 
disease risk or pathogenesis (Fig. 4). 
 
 
 
Figure 4. Percentage of current drug target classes. About half of all known drug targets 
are membrane proteins, however their structures are largely unresolved, remaining a 
bottle-neck in the drug-development pipeline. Figure adapted from (Adams et al., 2012).  
 
 
Many drugs have more than one specific target. Drug responses can be divided 
into primary and secondary drug responses. Primary responses occur when a 
drug binds to its target; secondary responses can be followed as functional 
changes in a tissue, organ, or whole organism (Armstrong, 2008). Drug target 
PGx research is focused on identifying the inheritance basis of interindividual 
variability in drug response and toxicity (Johnson, 2001). The human epidermal 
growth factor receptor 2 (HER2) and human epidermal growth factor (EGF) 
receptors are well-established examples of how drug target pharmacogenetics 
can be used to predict anti-cancer drug responses. The drug trastuzumab is 
administered selectively for breast cancers associated with overexpression of 
HER2 due to gene duplication (Sim and Ingelman-Sundberg, 2011). In recent 
years, several new therapeutics targeting specific oncology biomarkers, on-label 
Food and Drug Administration (FDA) drug uses, and companion diagnostics 
have been accepted (Patel, 2016).  
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1.2. Thiopurine drugs 
In the early 1950s, Gertrude B. Elion and George H. Hitchings synthesized a 
group of compounds known as thiopurines, for which they received the Nobel 
Prize in 1988 (Elion, 1951; 1986; 1989). The thiopurine drug 6-mercaptopurine 
(6-MP), its pro-drug azathioprine (AZA), and 6-thioguanine (6-TG), have been 
in common use for more than four decades as antineoplastic and immuno-
suppressive agents (Coulthard and Hogarth, 2005). 
 
 
1.2.1. Clinical use of thiopurine drugs 
6-MP, AZA, and 6-TG are used to treat malignancies, rheumatic diseases, der-
matologic conditions, and inflammatory bowel disease (IBD), and to prevent 
solid organ transplant rejection. Thiopurines have a narrow therapeutic index 
and may cause life-threatening ADRs, including myelosuppression. These drugs 
are antagonists for endogenous purines that are essential components of DNA 
and RNA. 6-MP, which was approved by the FDA in 1953 (Burchenal et al., 
1953; Elion, 1986; Veerman et al., 1996), is used mainly in combination with 
methotrexate to induce and maintain remission in childhood ALL (Cheok et al., 
2009; Fotoohi et al., 2010). AZA was introduced in the 1960s as an immuno-
suppressant for organ transplant recipients (Murray et al., 1963). Nowadays, it 
is used to treat IBDs, such as Crohn’s disease and ulcerative colitis (Blaker et 
al., 2012; Cosnes et al., 2005).  
 
 
1.2.2. Metabolism of thiopurine drugs 
The common oral daily dose for 6-MP in ALL maintenance therapy is 1.5–
2.5 mg/kg/d, with plasma concentrations peaking within, on average, 2.2 h. The 
bioavailability of oral 6-MP is in the range of 5–37%, with a half-life of 21 min 
in children (Blaker et al., 2012; Fotoohi et al., 2010). Renal transplant patients 
receive oral AZA (55% 6-MP by molecular weight) at a dosage of 2 mg/kg/d; 
its bioavailability range is 27–83% and, once absorbed, ~90% of AZA is 
converted immediately to 6-MP. The half-life of AZA is quite short at <2 h 
(Blaker et al., 2012; Chan et al., 1990). AZA is currently indicated for IBD, 
with dosing that is based on trial results (Axelrad et al., 2016). When single-
agent chemotherapy with 6-TG is determined to be appropriate, the usual initial 
oral dosage is approximately 2 mg/kg/d, which results in peak plasma levels 
within 2–4 h (Brox et al., 1981). The bioavailability of 6-TG is relatively low 
and variable at 14–46% (LePage and Whitecar, 1971) with a plasma half-life of 
90 min (Konits et al., 1982).  
 
 
1.2.2.1. Pharmacokinetics of thiopurines 
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Before exerting their cytotoxic and clinical effects, thiopurines are metabolized 
through a multi-enzyme pathway (Fig. 5). Once absorbed, AZA is transformed 
extensively into 6-MP by glutathione S-transferase (GST) via a non-enzymatic 
reaction (Blaker et al., 2012; Eklund et al., 2006; Kurtovic et al., 2008). Subse-
quently, it is taken up by cells via several transporters (e.g., SLC28A3 and 
SLC29A2) (Fotoohi et al., 2006; Peng et al., 2008; Zaza et al., 2005). There are 
three competitive enzymatic pathways by which 6-MP is metabolized: xantine 
oxidase (XO), hypoxanthine guanine phosphoribosyltransferase (HGPRT), and 
TPMT. In cells, both 6-MP and 6-TG are metabolized by XO into inactive 
metabolite-thiouric acid, which is excreted renally. XO can also metabolize 6-TG 
after prior conversion by guanase. TPMT catalyzes SAM-dependent S-methyl-
ation of 6-MP, 6-TG, and their metabolites into methyl metabolites, 6-methyl-
mercaptopurine (6-MMP), 6-methyltioguanine (6-MTG), 6-methyl-thioinosine 
monophosphate (meTIMP), and 6-methyl-thioguanine nucleotides (6-MTGN) 
(Al Hadithy et al., 2005; Blaker et al., 2012; Derijks et al., 2006; Moon and 
Loftus, 2016; Sahasranaman et al., 2008).  
Whereas TPMT is expressed ubiquitously in human tissues [e.g. liver, 
intestine, red blood cells (RBCs), white blood cells], XO is not expressed in 
hematopoietic tissue, making TPMT-dependent inactivation of drugs critical in 
white blood cells (Lennard et al., 1987). HGPRT is responsible for the 
bioactivation of the thiopurines. 6-MP metabolism is mediated step-wise by a 
series of enzymes. After HGPRT, conversion by inosine monophosphate 
dehydrogenase (IMPDH), guanosine monophosphate synthase (GMPS), and 
several kinases, active cytotoxic metabolites known as thioguanine nucleotides 
(6-TGNs) are formed (Al Hadithy et al., 2005; Blaker et al., 2012; Derijks et al., 
2006; Moon and Loftus, 2016; Sahasranaman et al., 2008). Conversion of 6-TG 
into active 6-TGNs is more direct, involving only HGPRT. The 6-TGNs include 
6-thioguanosine 5’-monophosphate (TGMP), -5’-diphosphate (TGDP), and -5’-
triphosphate (TGTP) (Elion, 1993).  
The therapeutic response to thiopurines is related to 6-TGN production and 
accumulation (Moon and Loftus, 2016; Zimm et al., 1983). In vivo, a 6-TGN 
steady state is achieved in 4–5 weeks of therapy, with a highly variant half-life 
of 3–13 days (Chouchana et al., 2012). For most patients with Crohn’s disease, 
signs of efficacy are apparent 12–17 weeks after initiation of therapy (Pre-
fontaine et al., 2010). 
Clinical studies have found that the cellular accumulation of TGN nucleotides 
is inversely proportional to TPMT activity because high TPMT activity shunts 
more molecules down the methylation pathway, leaving less for activation into 
cytotoxic TGNs (Krynetski et al., 1996; McLeod et al., 2000; McLeod et al., 
1994). Conversely, TPMT-deficient patients accumulate very high TGN 
concentrations, which leads to the severe ADRs when conventional doses are 
given (Evans et al., 1991; Krynetski et al., 1996; McLeod et al., 1993).  
 
1.2.2.2. Metabolism pathways of thiopurines 
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Figure 5. The metabolism of thiopurine drugs. Thiopurines are catabolized by XO, 
guanase, and aldehyde oxidase (AO) in the extracellular space. When inside the cell, 6-
TG is converted directly by HGPRT into TGMP; 6-MP is converted first to 6-
thioinosine-5’-monophosphate (TIMP) by HGPRT then to 6-thioxanthine-5’-mono-
phosphate (TXMP) by inosine monophosphate dehydrogenase (IMPDH), and finally to 
TGMP by guanosine monophosphate synthetase (GMPS). Both 6-MP and 6-TG and 
their respective monophosphates (TIMP and TGMP) are inactivated extensively inside 
the cell by thiopurine-S-methyltransferase (TPMT). meTIMP is a strong inhibitor of de 
novo purine synthesis. The remaining TGMP is converted to TGDP, reduced to deoxy-
6-thioguanosine-5’-diphosphate (dTGDP) by ribonucleotide reductase (RR), and 
phosphorylated by nucleoside diphosphate kinase (NDPK) to form dTGTP. Figure 
adapted from (Fotoohi et al., 2010). 
 
 
1.2.3. Mechanism of action of thiopurines 
As described in the previous section, thiopurines must be bioactivated via a 
series of non-enzymatic and enzymatic steps before they can exert their thera-
peutic effects. 6-TGNs are bioactive metabolites with cytotoxic and immuno-
suppressant properties. Following their formation, 6-TGNs are incorporated into 
DNA and RNA, thereby inhibiting replication, DNA repair mechanisms, and 
protein synthesis (Blaker et al., 2012; Moon and Loftus, 2016; Somerville et al., 
2003; Swann et al., 1996). 6-TGN cytotoxicity occurs selectively in the S-phase 
of the cell cycle (Inamochi et al., 1999). It has been shown that one possible 
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action of AZA and 6-MP may be increasing apoptosis of activated T-lympho-
cytes. Thiopurine therapy results in accumulation of 6-TGNs in lymphocytes. In 
immunologically driven diseases, T-cell activation occurs and 6-TGNs block 
the expression of Tumor necrosis factor-related apoptosis-inducing ligand, tumor 
necrosis factor receptor-S7, and α4-integrin, effects that reduce inflammation 
(Blaker et al., 2012; Moon and Loftus, 2016; Thomas et al., 2005).  
The effects of AZA and its metabolites on T-cell apoptosis have been 
attributed, at least in part, to modulation of Rac1 activation upon CD28 and CD3 
co-stimulation. The small GTPase Rac1 is involved in cell growth modulation, 
cytoskeletal organization, and protein kinase activation. Specific blockade of 
Rac1 activation is achieved by AZA-generated 6-TGTP binding Rac1 instead of 
GTP. Consequently, AZA suppresses activation of Rac1 target genes, resulting in 
a pro-apoptotic influence on T-lymphocytes. AZA thus converts a co-stimulatory 
signal into an apoptotic signal by modulating Rac1 activity (Blaker et al., 2012; 
Moon and Loftus, 2016; Tiede et al., 2003).  
As shown in the Figure 5 above, several other metabolites in this pathway 
are substrates for TPMT. For example, meTIMP is a strong inhibitor of de novo 
purine synthesis (DNPS), which contributes to the cytotoxic action of 6-MP 
(Erb et al., 1998; Evans et al., 1991). Inhibition of DNPS is immunosuppressive 
and block proliferation of various lymphocyte lines. TPMT activity level is 
expected to influence the production of meTIMP, and consequently, affect 
DNPS (Hanauer et al., 2001).  
 
 
1.2.4. ADRs associated with thiopurines 
There are generally two types of ADRs described: dose dependent and dose-
independent. Dose-dependent toxicity is associated with intra-cellular con-
centrations of active metabolites, which may evolve months or years after 
initiation of the therapy. Bone marrow and liver toxicities are particularly worri-
some. Dose-independent reactions include myalgia, flu-like symptoms, rash, 
acute pancreatitis, and gastric intolerance (Moon and Loftus, 2016). In clinical 
trials, up to 25% of patients treated with purine antimetabolites experience 
dose-independent side effects (Marinaki et al., 2004).  
Thiopurines often have hematologic toxicity, most commonly leucopenia 
(white blood cell count < 3 × 109/L) and neutropenia (absolute neutrophil count 
< 1.5 × 109/L). These ADRs can occur any time during the therapy, but most 
often occurs early in the course of therapy; they can be reversed by dose reduction 
or treatment discontinuation (Connell et al., 1993; Moon and Loftus, 2016; 
Present et al., 1989). Mild leucopenia is the most common hematological ADR 
to AZA. Drug-induced decreases in white blood cell count, however, has been 
reported to be associated with an improved clinical outcome (Colonna and 
Korelitz, 1994). Notwithstanding, severe bone marrow suppression is con-
sidered the worst ADR to thiopurines (Connell et al., 1993; Kirschner, 1998). 
The authors of a recent study concluded that Crohn’s disease patients should be 
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closely monitored, especially during the first three months of the thiopurine 
therapy when the majority of complications emerge, even if the patient has 
normal TPMT activity (Benmassaoud et al., 2015). A prospective study of 30 
Dutch IBD patients in which a pretreatment TMPT genotype analysis group was 
compared to a non-genotyped control group indicated that TPMT screening 
significantly reduced the risk of hematologic ADR in the subgroup of patients 
with TPMT variants (Coenen et al., 2015).  
In ALL patients, a high concentration of 6-TGNs in RBCs correlates with 
degree of leucopenia and positive drug responsivity, whereas low concentrations 
may lead to a higher risk of relapse (Bostrom and Erdmann, 1993; Lennard et al., 
1997). Hematotoxicity is the only dose-dependent ADR that has been associated 
with TPMT activity/genotype, thus far. TPMT-deficient patients taking standard 
doses of thiopurines are at approximately 100% risk of developing severe bone 
marrow suppression (Ansari et al., 2002; Gardiner et al., 2006; Gisbert and 
Gomollón, 2008; Moon and Loftus, 2016) due to very high concentrations of 6-
TGNs (Lennard et al., 1989). Childhood ALL patients that are TPMT hetero-
zygotes and patients with rheumatological diseases taking standard doses of 
thiopurines are also at risk of severe hematoxicity (Black et al., 1998; Relling et 
al., 1999).  
IBD patients with intermediate or low TPMT activity have been found to be 
at risk of developing myelosuppression (Colombel et al., 2000; Moon and 
Loftus, 2016). A large meta-analysis of 67 studies assessing the risk of myelo-
suppression among patients taking thiopurines indicated that, compared to 
patients with normal TPMT activity, those with intermediate TPMT activity 
were at a higher risk of developing myelosuppression, albeit not at as high of 
risk as those with low TPMT activity (Higgs et al., 2010). In another recent 
meta-analysis, the authors found an association of TPMT polymorphisms with 
overall AZA-induced ADRs, bone marrow toxicity, and gastric intolerance, but 
not with hepatotoxicity per se (Liu et al., 2015). However, several studies have 
indicated that hematotoxicity risk in IBD patients may be independent of TPMT 
status (De Ridder et al., 2006; Gisbert et al., 2006; Moon and Loftus, 2016). 
Other factors may determine risk, such as drug interactions (allopurinol), other 
enzymes (e.g. ITPase) and other genes (e.g. IL6ST, MOCOS) or TPMT-depen-
dent metabolites (meTIMP) may be involved (Coelho et al., 2016; Colombel et 
al., 2000; Hindorf et al., 2006; Venkat et al., 1990; Zabala et al., 2013).  
A variety of ADRs, including nausea, vomiting, malaise, myalgia, and 
arthralgia as well as hepatotoxicity and pancreatitis have been reported, 
especially early in the course of AZA therapy (Teml et al., 2007). As early as 
2000, an association between hepatotoxicity and levels of the TPMT methy-
lation product 6-MMP had been suggested (Dubinsky et al., 2000). Later, the 
same group confirmed that escalating AZA doses in non-responders lead to a 
preferential production of 6-MMPs, which was hepatotoxic (Dubinsky et al., 
2002), though the underlying mechanism of this phenomenon had not been 
uncovered. However, these ADRs have not been shown to be associated with 
empirically established TPMT status (Schwab et al., 2002). Although several 
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genes and enzymes have been studied searching for mechanisms underlying 
ADRs, results related to ITPA gene polymorphisms have been inconsistent 
(Gearry et al., 2004; van Dieren et al., 2005; von Ahsen et al., 2005). The 
development of gastrointestinal intolerance during thiopurine therapy was 
reported to be associated with TPMT activity by several groups (Hindorf et al., 
2006 Marinaki et al., 2004), but the putative association was not confirmed in a 
subsequent prospective study (Ansari et al., 2008a). Hence, TPMT involvement 
in gastrointestinal intolerance remains unclear and should be assessed further. 
 
 
1.3. Thiopurine methyltransferase (TPMT) 
1.3.1. TPMT gene 
TPMT (EC 2.1.1.67) is a cytosolic enzyme that catalyzes the S-methylation of 
aromatic and heterocyclic sulfhydryl compounds, including thiopurine drugs 
(REMY, 1963). In 1996, Szumlanski and colleagues mapped the TPMT gene to 
the short arm of chromosome 6 (6p22.3). They determined that TPMT is 
approximately 34 kb long and composed of 10 exons and nine introns (Fig. 6). 
Due to alternative splicing, exon 2 is present only in subset of mRNAs 
transcribed from the gene (Szumlanski et al., 1996). A year later, another group 
described TPMT as spanning only 25 kb and containing only 9 exons with 17 
additional nucleotides upstream of the transcription start site and a shorter 
intron 8 (Krynetski et al., 1997). Subsequently, Seki and colleagues determined 
that TPMT spanned 27 kb and contained 9 exons; they did not identify the 
intron 2 reported by Szumlanski group (Seki et al., 2000; Szumlanski et al., 
1996).  
Several groups have confirmed the presence of variable number tandem 
repeats (VNTRs) in the promoter region of the gene. These consist of 17–18-bp 
repeated sequences that are repeated three to nine times (VNTR*3–*9), most 
frequently four (*V4) or five (*V5), and contain putative binding sites for 
transcription factors (Alves et al., 2000; 2001; Marinaki et al., 2003; Spire-
Vayron de la Moureyre et al., 1998a; 1999; Yan et al., 2000; ). The 5’ of TPMT 
is GC rich (71%) with binding sites for several transcription factors (Sp1, NF-κB, 
AP-2 and KROX-24), but no TATA box or CCAAT element consensus 
sequences (Fessing et al., 1998; Szumlanski et al., 1996). In the human genome, 
there is a TPMT pseudogene in chromosome 18, which shares 96% identity with 
the TPMT open reading frame (ORF) on chromosome 6 (Lee et al., 1995). 
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Figure 6. Genetic structure of TPMT. The gene consists of 10 exons and 9 introns. 
Exon 2 is shown with dashed outline because it is spliced out of most transcript forms. 
The ORF is shown in green. Figure adapted from (Yan et al., 2000).  
 
 
1.3.2. TPMT protein 
TPMT has long been recognized for its major role in the metabolic transfor-
mation of exogenous thiopurine drugs. However, an endogenous substrate for 
TPMT has yet to be identified and TPMT deficiency has not been associated 
with any pathological condition (Blaker et al., 2012).  
The protein encoded by TPMT has a molecule mass of 28 kDa and is 245 
amino acids long (Honchel et al., 1993; Krynetski et al., 1996; Lee et al., 1995). 
Partly purified TPMT was characterized by Woodson and Weinshilboum in 
1983. The complete structure of TPMT was published in 2007 by Wu and 
colleagues. However, because the full-length TPMT protein failed to crystallize, 
the protein’s N-terminus was truncated, lacking the first 16 amino acids (Wu et 
al., 2007). TPMT was found to be a single-domain monomer with a classic Class-
I methyltransferase fold. The domain contains a nine-stranded β-sheet flanked 
on each side by three α-helices (Fig. 7). The β-sheet contains five parallel β-
chains with a pair of antiparallel β-hairpins on either end. An additional two 
helices were identified in the catalytic region of the protein, to which structurally 
similar S-adenosyl-homocystein, S-adenosyl-L-metionine, and 6-MP bind (Wu 
et al., 2007).  
 
 
 
 
Figure 7. Structure of TPMT in a complex 
with S-adenosyl-homocysteine. Strands (1-9) 
are colored green and helices (B-G) cyan. 
The N-terminal helices A and H (shown in 
yellow) constitute the catalytic site of the 
enzyme. Figure adapted from (Wu et al., 
2007).  
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In vitro and computational structural/functional analyses have shown that TPMT 
variants produce proteins of differing stability. Polymorphisms occur throughout 
the structure, but the amino acids whose alterations have the most influence on 
function are those involved in intra-molecular stabilizing interactions (Fazel-
Najafabadi et al., 2015; Wu et al., 2007). 
 
 
1.4. TPMT phenotypic and genetic variability 
TPMT activity in humans is influenced by variations in the TPMT (Weinshil-
boum and Sladek, 1980). Although TPMT enzyme activity has no apparent 
influence on individuals’ general phenotype, it becomes influential when one is 
administered a thiopurine drug (Lennard et al., 1993). Allelic differences have 
an impact on treatment efficacy and ADR risk (Weinshilboum and Sladek, 
1980). A series of population studies have shown that TPMT activity is trimodal, 
with approximately 89% of subjects exhibiting normal activity, 11% exhibiting 
intermediate activity, and 0.3% having very low or deficient activity. The 
association between enzyme activity and mutation is best established for 
individuals with poor or deficient enzyme activity, who are usually mutant 
homozygotes or compound heterozygotes for inactive alleles (Appell et al., 
2010; Colombel et al., 2000; Feng et al., 2010; Garat et al., 2008; Hamdan-
Khalil et al., 2003; Hamdan-Khalil et al., 2005; Hon et al., 1999; Kham et al., 
2009; Landy et al., 2011; Lee et al., 2012; Lindqvist et al., 2004; Lindqvist et 
al., 2007; Otterness et al., 1997; Sasaki et al., 2006; Schaeffeler et al., 2006; 
Schaeffeler et al., 2004; Schaeffeler et al., 2003; Spire-Vayron de la Moureyre 
et al., 1998b). The correlation between genotype and enzyme activity is mixed 
in heterozygous subjects because some heterozygotes exhibit normal-range 
TPMT activity (enzyme activity range, 53–100% of typical) (Alves et al., 2001; 
Milek et al., 2006; Schaeffeler et al., 2004; Spire-Vayron de la Moureyre et al., 
1998a). There is also a subgroup of individuals with rapid or ultra-rapid enzyme 
activity, which confers therapeutic resistance (Roberts et al., 2008).   
Due to the aforementioned population variance in TPMT activity, standard 
thiopurine doses that are effective in most patients are not suitable for patients 
with hypo- or hyper-active TPMT. Therefore TPMT genotype and/or TPMT 
enzyme activity should be considered when prescribing a thiopurine, together 
with other potential factors that may influence thiopurine drug effects (Karas-
Kuzelicki and Mlinaric-Rascan, 2009). 
 
 
1.4.1. Factors that may influence TPMT activity 
TPMT genotype is not a perfect predictor of thiopurine therapy efficacy or ADR 
risk. Indeed, roughly half of all patients who develop leucopenia during thio-
purine therapy have normal TPMT activity and a wild-type TPMT genotype 
(Blaker et al., 2012). Hence, there is a need to identify additional markers of 
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thiopurine responsivity. In the following sections, I will give an overview of the 
different types of factors that are thought to influence TPMT activity as of the 
time of writing this thesis. 
 
 
A large systematic review summarized the effects of various factors on TPMT 
activity (Loit et al., 2011). Results regarding the influence of gender and age 
have been contradictory. Some have found that TPMT activity is significantly 
higher in males than females (Indjova et al., 2003; Schaeffeler et al., 2004; 
Tamm et al., 2008), whereas others found no correlation between gender and 
TPMT activity (Alves et al., 2001; Ganiere-Monteil et al., 2004; Zhang et al., 
2007). Schaeffeler and colleagues also showed a statistically significant dif-
ference in TPMT activity between smokers and non-smokers, within both male 
and female groups (Schaeffeler et al., 2004). Children have been reported to 
have lower TPMT activity than adults, though the distinction was attributed to 
their juvenile group have a greater portion of intermediate metabolizers (Hindorf 
et al., 2004). A large study with more than 14,000 patients demonstrated that 
TPMT activity in groups of patients with IBD, autoimmune hepatitis, multiple 
sclerosis, myasthenia gravis, pemphigus, and chronic renal failure differed from 
that in a healthy control population (Gisbert et al., 2007). 
 
 
SAM is an endogenous universal methyl donor involved in a multitude of 
reactions catalyzed by numerous SAM-dependent enzymes. It has been described 
as a modulator of a number of important genes via transcriptional, posttran-
scriptional, and posttranslational mechanisms. Most notably, SAM provides 
posttranslational stabilization of catechol O-methyltransferase, a polymorphic 
enzyme involved in the catabolism of catechol estrogens and catecholamines 
(Rutherford et al., 2006), as well as cystathionine b-synthase, the rate-limiting 
enzyme in the trans-sulfuration pathway (Prudova et al., 2006).  
It has been shown that SAM stabilizes the conformational structure of TPMT 
by binding to its active site and protecting it from degradation (Scheuermann et 
al., 2004). Milek et al. (2012) demonstrated effects of fluctuations in physio-
logical levels of SAM and related metabolites on TPMT activity levels in cell 
lines and in erythrocytes collected from healthy individuals. In TMPT wild-type 
subjects, TPMT activity was significantly higher in subjects with high SAM 
concentrations than in those with low SAM levels. Those findings extend a 
previous study demonstrating that restriction of L-methionine (SAM precursor) 
in cell growth media decreased TPMT activity and protein levels reversibly, but 
had no effect on TPMT mRNA expression (Milek et al., 2009). Interestingly, in 
a large cohort of healthy individuals, the influence of SAM availability on TPMT 
activity was shown to be particularly pronounced in TPMT heterozygotes (Karas-
1.4.1.1. Gender, age, and diseases 
1.4.1.2. S-adenosylmethionine (SAM) 
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Kuželički et al., 2014). Thus, the bioavailability of SAM has been shown to 
influence TPMT activity in vivo and to affect the formation of thiopurine 
metabolites (Blaker et al., 2012).  
 
 
It is well known that there are extrinsic factors beyond genetics that can influence 
TPMT activity. Because patients are usually on polytherapy, it should be kept in 
mind that interactions between drugs and other factors can occur. This thesis 
will address those interactions for which there are clear outcome data. 
Several drugs are known to inhibit TPMT activity and lead to ADRs when 
administered together with thiopurines. In the 1980s, benzoic acid derivatives 
were shown to inhibit TPMT activity strongly (Ames et al., 1986; Blaker et al., 
2012). Several studies have shown that TPMT can also be inhibited by amino-
salicylates, such as mesalamine, sulphasalazine, olsalazine, and balsalazide (de 
Graaf et al., 2010; Szumlanski and Weinshilboum, 1995). Notably, patients with 
Crohn’s disease who were co-administered 6-MP and olsalazine were reported 
to exhibit several episodes of myelosuppression, and olsalazine was demon-
strated to be a non-competitive inhibitor of TPMT (Blaker et al., 2012; Lewis et 
al., 1997). Co-administration of the thiopurine drugs AZA or 6-MP with mesa-
lamine, sulphasalazine, or olsalazine has also been reported result in TPMT 
inhibition, presenting clinically as leucopenia (Lowry et al., 2001a; 2001b). The 
same phenomenon was described for IBD patients with different TPMT pheno-
types. A strongest TPMT inhibitor examined thus far appears to be sulfasalazine 
(Xin et al., 2005a).  
Diuretics, like furosemide, have also emerged as potential inhibitors of 
TPMT (Blaker et al., 2012; Xin et al., 2005b). In 2007, one study aimed at 
analyzing the potential inhibitory effect of nonsteroidal anti-inflammatory drugs 
on TPMT in vitro showed that naproxen, tolfenamic acid, and mefenamic acid 
were non-competitive inhibitors of TPMT. Also, propionic derivatives (ibu-
profen and ketoprofen) have been suggested to have the potential to inhibit 
TPMT activity in a clinically significant manner (Blaker et al., 2012; Oselin and 
Anier, 2007). The xanthine oxidase inhibitor allopurinol is not a direct inhibitor 
of TPMT, but rather an important modulator of thiopurine tolerance; it is 
prescribed to patients with IBD to yield better efficacy of reduced-dose thio-
purine therapy by way of increasing 6-MP bioavailability and augmenting 6-
TGN levels (Blaker et al., 2012; Moon and Loftus, 2016; Zimm et al., 1983). 
Co-administration of these drugs must be monitored carefully to enable timely 
adjustments to be made as needed. Further clarification of TPMT-related drug 
interactions should clarify the mechanisms thiopurine intolerance and ADRs.   
 
 
 
 
1.4.1.3. Drugs 
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1.4.2. Known genetic variants of TPMT 
The TPMT gene has a number of known polymorphisms and mutations affecting 
exons, exon-intron junctions, and the 5’-flanking region. Those sequence variants 
affecting the ORF of TPMT have received the most attention, particularly in 
studies of TPMT enzyme activity (see references in Table 1). Several allelic 
variants have been functionally characterized in vitro (Ujiie et al., 2008; 
Wennerstrand et al., 2012) or computationally (Fazel-Najafabadi et al., 2015). 
 
 
According to the published literature available at the time of writing this thesis, 
there are more than 35 non-synonymous sequence variants of TMPT that alter 
TMPT activity (Table 1). TPMT*1 is the wild-type allele and encodes normal-
activity TPMT (Szumlanski et al., 1996). Coding-region variants exhibit 
accelerated protein degradation or aggregation (Tai et al., 1997; Wang et al., 
2005). Meanwhile, exon-intron mutations can alter mRNA splicing in ways that 
affect the functional status of the protein (Otterness et al., 1997; Salavaggione et 
al., 2005). 
1.4.2.1. TPMT sequence mutations 
 
Table 1. TPMT alleles confirmed by TPMT nomenclature committee (November 2016). 
Allele rs number Location Amino acid change Reference 
TPMT*1 rs2842934  Wild-type  
TPMT*1A – Exon 1 –178C>T, – Spire-Vayron de la 
Moureyre et al., 1998b 
TPMT*1S rs2842934 Exon 7 474T>C, Ile158Ile Yates et al., 1997 
TPMT*2 rs1800462 Exon 5 238G>C, Ala80Pro Krynetski et al., 1995 
 
TPMT*3A 
rs1800460 
rs1142345 
Exon 7 
Exon 10 
460G>A, Ala154Thr 
719A>G, Tyr240Cys 
Tai et al., 1996 
TPMT*3B rs1800460 Exon 7 460G>A, Ala154Thr 
TPMT*3C rs1142345 Exon 10 719A>G, Tyr240Cys 
 
TPMT*3D 
rs72552739 
rs1800460 
rs1142345 
Exon 5 
Exon 7 
Exon 10 
292G>T, Glu98stop 
460G>A, Ala154Thr 
719A>G, Tyr240Cys 
Otterness et al., 1997 
 
TPMT*3E rs3931660 
rs12529220 
rs2518463 
rs1800460 
rs2842934 
rs1142345 
Intron 3 
Intron 3 
Intron 4 
Exon 7 
Exon 7 
Exon 10 
140 +114T>A 
141 –101A>T 
366+58T>C 
460G>A, Ala154Thr 
474T>C, Ile158Ile 
719A>G, Tyr240Cys 
Colleoni et al., 2012 
TPMT*4 rs1800584 Intron 9 
/exon10 
626-1G>A, in splice 
junction 
Otterness et al., 1997 
 
TPMT*5 rs72552740 Exon 4 146T>C, Leu49Ser Otterness et al., 1997 
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Allele rs number Location Amino acid change Reference 
TPMT*6 rs75543815 Exon 8 539A>T, Tyr180Phe Otterness et al., 1997 
TPMT*7 rs72552736 Exon 10 681T>G, His227Glu Spire-Vayron de la 
Moureyre et al., 1998b 
TPMT*8 rs56161402 Exon 10 644G>A, Arg215His Hon et al., 1999 
TPMT*9 rs151149760 Exon 5 356A>C, Lys119Thr Schaeffeler et al., 2004 
TPMT*10 rs72552737 Exon 7 430G>C, Gly144Arg Colombel et al., 2000 
TPMT*11 rs72552738 Exon 6 395G>A, Cys132Tyr Schaeffeler et al., 2003 
TPMT*12 – Exon 6 374C>T, Ser125Leu Hamdan-Khalil et al., 
2003 TPMT*13 rs72552742 Exon 3 83A>T, Glu28Val 
TPMT*14 rs9333569 Exon 3 1A>G, Met1Val Lindqvist et al., 2004 
TPMT*15 rs9333570 Intron 7 
/exon8 
495-1G>A, in splice 
junction 
TPMT*16 rs144041067 Exon 7 488G>A, Arg163His Schaeffeler et al., 2004 
TPMT*17 – Exon 3 124C>G, Gln42Glu 
TPMT*18 – Exon 4 211G>A, Gly71Arg 
TPMT*19 – Exon 5 365A>C, Lys122Thr Hamdan-Khalil et al., 
2005 
TPMT*20 rs150900439 Exon 10 712A>G, Lys238Glu Schaeffeler et al., 2006 
TPMT*21 rs200591577 Exon 4 205C>G, Leu69Val 
TPMT*22 – Exon 7 488G>C, Arg163Pro 
TPMT*23 rs74423290 Exon 8 500G>C, Ala167Gly Lindqvist et al., 2007 
TPMT*24 rs6921269 Exon 8 537G>T, Gln179His Garat et al., 2008 
TPMT*25 – Exon 10 634T>C, Cys212Arg 
TPMT*26 rs72556347 Exon 9 622T>C, Phe208Leu Kham et al., 2009 
TPMT*27 – Exon 5 319T>C, Tyr107Asp Feng et al., 2010 
TPMT*28 – Exon 5 349C>A, Gly117Arg Landy et al., 2011 
TPMT*29 rs267607275 Exon 3 2T>C, Met1Thr Lee et al., 2012 
TPMT*30 – Exon 3 106G>A, Gly36Ser Sasaki et al., 2006 
TPMT*31 rs79901429 Exon 9 611T>C, Ile204Thr Appell et al., 2010 
TPMT*32 rs115106679 Exon 5 340G>A, Glu114Lys Lennard et al., 2012 
TPMT*33 rs12339338 Exon 7 487C>T, Arg163Cys 
TPMT*34 rs111901354 Exon 5 244C>T, Arg82Trp 
TPMT*35 – Exon 3 200T>C, Phe67Ser Skrzypczak-Zielinska et 
al., 2013 TPMT*36 – Exon 8 595G>A, Val199Ile 
TPMT*37 rs398122996 Exon 10 648T>A, Cys216Ter Roberts et al., 2014a 
TPMT*38 – Exon 8 514T>C, Ser172Pro Kim et al., 2015 
TPMT*39 – Exon 6 218C>T, Ala78Val Coelho et al., 2016 
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TPMT*2, TPMT*3A, and TPMT*3C are the most frequent (80–95%) alleles 
causing intermediate and low/deficient enzyme activity (Tai et al., 1996; Yates 
et al., 1997). TPMT*2 has a variant in exon 5 (Ala80Pro) (Krynetski et al., 
1995). TPMT*3A, which occurs frequently in people of European descent, has 
non-synonymous changes in exon 7 (Ala154Thr) and exon 10 (Tyr240Cys) (Tai 
et al., 1996), which when they occur alone are referred to as TPMT*3B and 
TPMT*3C, respectively (Aarbakke, 1995). The enzyme activity levels of the 
proteins encoded by TPMT*2 and TPMT*3A are decreased markedly to <1% 
and <0.5% of that of normal of the wild-type protein, respectively (Fazel-
Najafabadi et al., 2015; Tai et al., 1997); TPMT*3C has relatively little effect on 
enzyme activity (Tai et al., 1997). Both TPMT*2 and TPMT*3A are transcribed 
at normal levels, but people with these alleles carry low levels of the enzyme 
due to posttranslational modifications that affect secondary and tertiary structure 
and aggregate formation. The resultant mutant proteins are subjected to 
degradation in proteasomes and lysosomes (Tai et al., 1997; Wang et al., 2005).  
Alleles TPMT*4–*18 and *20–*39 have been identified in only a few 
subjects, who carry the heterozygous genotype of their respective variants 
(Appell et al., 2010; Coelho et al., 2016; Colombel et al., 2000; Feng et al., 2010; 
Garat et al., 2008; Hamdan-Khalil et al., 2003; Hamdan-Khalil et al., 2005; Hon 
et al., 1999; Kham et al., 2009; Kim et al., 2015; Lee et al., 2012; Lennard et al., 
2012; Otterness et al., 1997; Roberts et al., 2014a; Sasaki et al., 2006; Schaef-
feler et al., 2006; Schaeffeler et al., 2004; Skrzypczak-Zielinska et al., 2013; 
Spire-Vayron de la Moureyre et al., 1998b), though some are compound hetero-
zygotes for different non-wild-type alleles (Landy et al., 2011; Lindqvist et al., 
2004; Lindqvist et al., 2007; Otterness et al., 1997; Schaeffeler et al., 2003). 
The TPMT alleles have an ethnically differentiated distribution. TPMT*6, *26, 
*27, *29, and *38 are only found in individuals of Asian origin, whereas 
TPMT*8 has only been found in African-Americans (Feng et al., 2010; Hon et 
al., 1999; Kham et al., 2009; Kim et al., 2015; Lee et al., 2012; Otterness et al., 
1997). All other alleles are mostly present in Caucasians, but are very rare with 
very low frequencies (see references in Table 1). In vitro functional analysis 
have demonstrated that alleles *2–*24, *27, *28 are associated with decreased 
enzyme activity and accelerated protein degradation compared to the wild-type 
enzyme (Appell et al., 2010; Feng et al., 2010; Ujiie et al., 2008). TPMT*19 
(exon 5 mutation) was identified in a single patient with Crohn’s disease, who 
exhibited TPMT activity comparable to that seen with the wild-type enzyme 
(Hamdan-Khalil et al., 2005). Computational analysis indicated diverse effects 
of missense mutations on TPMT structure and function, with several variants 
being expected to affect stability, aggregation propensity, and ligand binding 
(Fazel-Najafabadi et al., 2015).  
Phenotype-genotype discrepancies for TPMT variants that defy the typical 
expectations for sequence variance are abound. Notably, phenotype-genotype 
correlation is very high for wild-types and mutant homozygotes (93–100%), but 
much less reliable (53–100%) for TPMT heterozygotes (Coelho et al., 2016; Ford 
et al., 2009; Laróvere et al., 2003; Milek et al., 2006). This divergence from 
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phenotype-genotype correlation points to the importance of other unidentified 
factors, including other genetic variations, that have an indirect effect on TPMT 
activity or otherwise modulate thiopurine metabolism. 
 
 
 
Other sequence variations, besides SNPs, have been identified in the 5’-flanking 
region of TPMT. The contributions of GC-rich VNTRs, which consist of three 
elements (A, B and C) that differ in sequence and length between individuals, to 
TPMT enzyme activity have been explored. Spire-Vayron de la Moureyre and 
colleagues (1998a) identified 17–18-bp units that repeat four to eight times 
(*V4–*V8). Variable three to nine repeats (*V3–*V9) have also been found in 
the promoter with differing nucleotide sequences (Alves et al., 2000; Marinaki 
et al., 2003; Spire-Vayron de la Moureyre et al., 1998a; 1998b; 1999; Yan et al., 
2000). Four-repeat VNTRs are most frequent, followed by five-repeat VNTRs 
(Spire-Vayron de la Moureyre et al., 1998b).  
Because the VNTRs contain binding sites for the transcription factor Sp1, 
they could potentially have an impact on inter-individual variability in TPMT 
activity by way of modulating transcription and, consequently, expression levels. 
However, population studies analyzing the influence of VNTRs on TPMT 
activity have been contradictory, with some showing only modest effect (Alves 
et al., 2001; Marinaki et al., 2003; Yan et al., 2000). Repeats composed of 6 or 7 
tandem copies have been reported to reduce promoter activity relative to alleles 
with less tandem copies (Spire-Vayron de la Moureyre et al., 1999). Specific 
combinations may also be correlated to decreased activity (Alves et al., 2001). 
The presence of at least one allele with more than five repeat elements has been 
associated with notable low activity (Yan et al., 2000), albeit a modest reduction 
relative to that produced by ORF-based variants. One study found no 
differences in VNTR allele frequencies between British Asians and Caucasians 
(Marinaki et al., 2003).  
The effect of VNTRs on TPMT activity during thiopurine therapy has been 
investigated. In patients with rheumatoid arthritis taking AZA, enzyme activity 
levels before and after treatment were not found to be associated with VNTRs 
(Arenas et al., 2004). In addition, in children with ALL, there was no correlation 
between the number of VNTRs and 6-MP treatment outcome (Dokmanović et 
al., 2008). Recently, a long-term study investigating the functional role of VNTR 
number and type with respect to TPMT gene transcription was completed. The 
researchers demonstrated that both the number and type of VNTRs in the TPMT 
promoter influenced the level of gene transcription observed. The study also 
showed that the ‘A’ repeat has a negative effect on TPMT transcription and that 
a positive regulatory element immediately upstream to the VNTR region in the 
promoter was indispensable for TPMT transcription (Zukic et al., 2010). The 
same group showed later that 6-MP influences TPMT transcription in a VNTR-
dependent manner mediated by the binding of newly recruited protein complexes 
 1.4.2.2. Variable number tandem repeats
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to the promoter upon 6-MP treatment. They also demonstrated that ALL patients 
carrying different VNTR genotypes respond differently to 6-MP therapy. 
Indeed, patients with VNTRs that decreased TPMT promoter activity were 
treated with lower doses of the drug and given a longer discontinuation period 
(Kotur et al., 2012). In 2015, in a study examining TPMT expression in 
childhood ALL patients at diagnosis and during the maintenance therapy, the 
same group detected a three-fold increase in gene expression during maintenance 
therapy, with this upregulation being modulated by the architecture of 
the VNTR region. They concluded that the TPMT VNTR region should be 
considered at the commencement of maintenance therapy for childhood ALL 
patients because it may serve a pharmacogenomic biomarker of thiopurine 
therapy responsivity (Kotur et al., 2015). Notwithstanding, larger cohort studies 
are needed to confirm these findings independently and more functional analysis 
should be performed to uncover the modulatory mechanism of VNTRs on 
TPMT activity.  
 
 
As mentioned above, there are more than TPMT variants that are predictive of 
decreased TPMT enzyme activity. Meanwhile, there is far less information 
regarding the cause of ultra-high enzyme activity. Thus far, there is only one 
study published that has shown an association between ultra-high enzyme 
activity and GCC trinucleotide repeats in the promoter region of TPMT. Signi-
ficantly increased TPMT activity was observed for five and seven repeats, 
compared to six repeats, which is considered to be wild-type; however the 
mechanism by which the trinucleotide repeat may affect TPMT expression is 
unknown (Roberts et al., 2008). At the time of the writing of this thesis, this was 
the only study in the literature addressing the influence of these triple repeats on 
TPMT expression. 
 
 
1.4.3. Variations in other genes and thiopurine drug response 
Although thiopurines are considered to have good clinical efficacy, they are 
associated with some drawbacks with respect to ADRs as well as drug 
resistance. The mechanism of thiopurine metabolism is quite well-established 
with the most important player being the enzyme TPMT, though there have 
been many cases in which TPMT genetic and enzymatic variability could not 
explain drug response variance. Therefore, there is a need to identify novel 
markers of thiopurine drug responsivity, in genetic and metabolite levels. 
Several studies have investigated the possible role of other genes in thiopurine 
drug response (Fig. 8). The preliminary results obtained thus far need to be 
replicated and confirmed in further prospective studies before their clinical 
applicability is known. In the following section, there are examples of some 
findings in this regard.  
1.4.2.3. Triple repeats 
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Figure 8. Schematic diagram showing the main steps and metabolites of thiopurine drug 
metabolism (green boxes) and genes implicated in thiopurine induced toxicity. Genes 
described in the text are indicated with blue encircling. Details of thiopurine metabolism 
are in Figure 5 above. Abbreviations: 6-MP, 6-mercaptopurine; 6-MMP, 6-methyl 
mercaptopurine; 6-MMPN, 6- methyl mercaptopurine nucleotides; 6-TGN, 6-thio-
guanines; 6-TIMP, 6-thioinosine monophosphate; 6-TITP, 6-thioinosine triphosphate; 6-
TU, 6-thiouracil; 6-TXMP, 6-thioxanthosine monophosphate; ABCC4, ATP-binding 
cassette, sub-family C (CFTR/MRP), member 4; AOX1, aldehyde oxidase 1; AZA, 
azathioprine; FSLT5, Follistatin-Like 5; GMPS, guanosine monophosphate synthetase; 
GST, glutathione S-transferase; HGPRT, hypoxanthine guanine phosphoribosyl-
transferase; IL6ST, Interleukin 6 signal transducer; IMPDH, inosine 5-monophosphate 
dehydrogenase; ITPase, inosine triphosphatase; MOCOS, molybdenum cofactor sulfurase; 
MTHFR, methyl-enetetrahydrofolate reductase; NUDT15, nudix (nucleoside diphosphate 
linked moiety X)-type motif 15; PACSIN2, protein kinase C and casein kinase substrate 
in neurons 2; TPMT, thiopurine methyltransferase; XDH, xanthine dehydrogenase 
[synonym: xanthine oxidase (XO)]. Figure adapted from (Coelho et al., 2016). 
 
 
1.4.3.1. Glutathione S-transferase (GST) 
GSTs are cytosolic enzymes responsible for the conjugation of several xeno-
biotics. Some of them are abundantly expressed in the human liver and are 
involved in the early metabolism of AZA (Fig. 8). These enzymes catalyze the 
release of 6-MP from its pro-drug AZA (Blaker et al., 2012; Moon and Loftus, 
2016). The GST isoforms A1-1, A2-2, and M1-1 are abundantly expressed in 
the liver and exhibit robust activity towards AZA in their wild-type forms 
(Eklund et al., 2006).  
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Several polymorphisms in GST A2-2 gene have been detected, with one variant 
GST-A2-2*E showing the three- to four-fold increased activity (Zhang et al., 
2010). It has been suggested that excessively high enzyme activity with a high 
drug dose may lead to glutathione depletion and cause cell damage (Eklund et 
al., 2006). In one study, GST-M1 was associated with adverse events (Stocco et 
al., 2007). The authors posited that high-activity GST-M1 may lead to a slight, 
but significant increase in the risk of developing lymphopenia. Therefore, it 
would be expected that the null genotype (low GST-M1 activity) may protect 
against adverse events (Moon and Loftus, 2016; Stocco et al., 2007). In an 
evaluation of the association between GST-M1 genotype and thiopurine meta-
bolites in IBD patients treated with AZA, GST-M1 deletion was associated with 
a lower TGN/dose ratio, higher AZA requirement, and dampened therapeutic 
response (Al-Judaibi et al., 2016; Stocco et al., 2014a). Because the frequency 
of the null GST-M1 genotype is high in Caucasians and present in about half of 
Asians, there is a pressing need to determine its role in thiopurine drug response 
(Hamdy et al., 2003). However, there is not enough evidence to explain the 
relationship between GST genotype and other ADRs (Moon and Loftus, 2016). 
It has been suggested that genetic polymorphisms in genes encoding GSTs may 
be useful for predicting therapeutic response to AZA, though in vitro and 
clinical validation studies are needed to test this expectation (Stocco et al., 
2014b).  
 
The enzyme XO participates in the early detoxification of thiopurine drugs (Fig. 
8). It oxidases 6-MP into inactive thiouric acid, which is excreted in urine, 
thereby removing up to two-thirds of a delivered dose (Parks and Granger, 
1986). XO is a ubiquitous cytoplasmic enzyme found in particularly high levels 
in the intestine and liver (Huh et al., 1976). XO deficiency is very rare, but 
when it occurs, it yields severe toxicity following administration of a full dose 
of AZA (Ansari et al., 2008b; Moon and Loftus, 2016; Serre-Debeauvais et al., 
1995). Activity of XO can vary 10-fold between individuals, with ethnic and 
gender differences having been detected (Ansari et al., 2008b; Relling et al., 
1992). A variety of SNPs have been identified and associated with deficient XO 
activity, which consequently may alter thiopurine metabolite levels (Hawwa et 
al., 2008; Kudo et al., 2008; Moon and Loftus, 2016). XO activity requires its 
cofactor molybdenum; thus, molybdenum deficiency affects XO activity (Smith 
et al., 2009). It is also known that some XO products, namely oxidized purine 
metabolites, inhibit TPMT, which may increase 6-TGN levels (Deininger et al., 
1994). Thus, the potential clinical utility of these findings is unclear. 
Confirmatory studies are needed to develop firm conclusions regarding the role 
of XO in characterizing individual patients’ drug responsivity profiles. 
 
 
1.4.3.2. Xanthine oxidase (XO) 
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The enzyme AOX, which is ubiquitously expressed in animals, is involved in 
early thiopurine metabolism (Fig. 8). It catalyzes 8-hydroxylation of 6-MP and 
AZA into inactive metabolites (Clarke et al., 1958). SNPs on the AOX gene 
have been associated with a poor clinical response to AZA. When AOX1 3404G 
SNP is combined with TPMT activity data, the likely drug response to AZA can 
be predicted effectively. Patients with normal TPMT activity and wild-type 
AOX1 were found to have 86% likelihood of a favorable clinical response to 
AZA therapy, whereas those with deficient TPMT activity who were carriers of 
the AOX1 3404G SNP were found to only have a 33% likelihood of exhibiting a 
favorable response (Smith et al., 2009). However, the frequency of this SNP in 
different populations is unknown, and further work is needed to explore the 
clinical implications of these findings (Chouchana et al., 2012; Moon and 
Loftus, 2016). 
 
 
HGPRT catalyzes the first step in the conversion of 6-MP and 6-TG into 6-
TGNs and it is the key enzyme in the purine salvage pathway (Fig. 8). Inter-
individual variability in HGPRT activity could help to explain the board range 
of thiopurine therapeutic responses and ADRs observed in IBD patients. 
Mutations have been identified throughout the HGPRT gene, and many of these 
may influence the enzyme’s activity (Moon and Loftus, 2016). However, there 
are only sparse data on the relationship between HGPRT activity and thiopurine 
related ADRs. In IBD patients prescribed thiopurines, high HGPRT activity was 
associated with an increased risk of leucopenia, which correlates with elevated 
6-TGN levels (Ding et al., 2012). However, our knowledge is still insufficient 
to determine the significance of HGPRT for predicting and avoiding thipurine-
related ADRs (Blaker et al., 2012; Moon and Loftus, 2016). 
 
 
The enzyme ITPA is widely expressed in variety of tissues in the human body, 
including in leucocytes and erythrocytes (Lin et al., 2001). It converts inosine 
triphosphate (ITP) back into inosine monophosphate (IMP), which prevents the 
intracellular accumulation of potentially harmful nucleotides that can be mis-
incorporated into nucleic acid molecules (Holmes et al., 1979). In thiopurine 
metabolism, there is a parallel cycle wherein ITPA hydrolyzes 6-thioinosine 
triphosphate (6-TITP) back into 6-thioinosine monophosphate (6-TIMP) (Fig. 8). 
Thus, ITPA deficiency leads to an accumulation of toxic 6-TITPs (Marinaki et 
al., 2004). To date, five single nucleotide polymorphisms have been identified 
in the ITPA gene, two of which have been associated with enzyme deficiency 
(Sumi et al., 2002), though contradictory results exist. Some studies have shown 
1.4.3.3. Aldehyde oxidase (AOX) 
1.4.3.4. Hypoxantine guanine phosphoribosyltransferase (HGPRT) 
1.4.3.5. Inosine triphosphatase (ITPA) 
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that ITPA deficiency in patients on AZA therapy is associated with greater risk 
of adverse events like flu-like symptoms, rash, leucopenia, and pancreatitis 
compared with control subjects (Ansari et al., 2008a; Marinaki et al., 2004; 
Moon and Loftus, 2016; Zelinkova et al., 2006), while other studies have not 
shown any significant association (Allorge et al., 2005; Kurzawski et al., 2009; 
Moon and Loftus, 2016). Large prospective studies and clinical trials are needed 
to assess the influence of ITPA on clinical responses to thiopurines. 
  
 
As mentioned above, the cofactor SAM acts as an essential methyl donor for 
TPMT. In this reaction, SAM is converted back to S-adenosyl-L-homocystein 
(SAH), which is thereafter recycled back into SAM via the folate cycle. 5,10-
MTHFR is an enzyme in the folate cycle that may influence TPMT activity 
indirectly by altering the availability of SAM. Two SNPs that have been 
associated with decreased MTHFR activity may decrease TPMT activity in this 
way (Karas-Kuzelicki et al., 2009; Ogino and Wilson, 2003; Schwahn and Rozen, 
2001). Additionally, antifolate drugs such as methotrexate or trimethoprim 
inhibit the folate cycle and may thereby also influence TPMT activity and 6-
TGN production (Brouwer et al., 2005; Dervieux et al., 2003).  
 
 
PACSIN2 is a member of the ‘protein kinase C and casein kinase substrate in 
neurons’ family of proteins that are involved in vesicle formation via inter-
actions with the large GTPase dynamin and N-WASP, which forms a critical 
part of the actin polymerization machinery (Kessels and Qualmann, 2004). 
Using genome-wide analysis (GWAS), Stocco and colleagues identified a new 
marker (rs2413739) in the PACSIN2 gene that is related to variability in TPMT 
activity. They showed that PACSIN2 polymorphism and gene expression infor-
mation together can be used to predict TPMT activity level in HapMap CEU 
cell lines, and further found that PACSIN2 genotype was related to TPMT 
activity and mercaptopurine-induced ADRs in children with ALL. A significant 
association was confirmed in both patients with wild-type and patients with 
variant TPMT genotypes, who developed gastrointestinal toxicity during con-
solidation therapy (Stocco et al., 2012). A recent study reported an interaction 
between the TPMT genotype and PACSIN2 rs2413739 presence in hemato-
toxicity risk. Specifically, patients with wild-type TPMT and a PACSIN2 
rs2413739 mutant homozygous genotype were at elevated risk of experiencing 
hematotoxicity compared to patients that were heterozygous for or without the 
PACSIN2 rs2413739 allele during ALL maintenance therapy (Smid et al., 
2016).  
 
1.4.3.6. Methylene tetrahydrofolate reductase (MTHFR) 
1.4.3.7. Protein kinase C and casein kinase substrate  
in neurons 2 (PACSIN2) 
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Although TPMT deficiency is less common in individuals of Asian descent than 
in individuals of European ancestry, the Asian population appears to be 
particularly intolerant to a full dose of thiopurines. This finding suggests that 
there are other genetic variants associated with thiopurine intolerance that may 
be common in Asian populations (Moon and Loftus, 2016). In 2014, a study in 
Korean IBD patients, and more recently two studies of pediatric ALL patients in 
the USA and Japan, identified an association between a novel pharmacogenetic 
variant in NUDT15 (rs116855232) and thiopurine ADRs, especially hemato-
poietic toxicity (Tanaka et al., 2015; Yang et al., 2015; Yang et al., 2014). 
NUDT15 is a member of the nudix hydrolase enzyme family; it underlies a 
safeguard mechanism in mammalian cells to minimize DNA damage and 
thereby avoid subsequent repair and apoptosis. Several studies have confirmed 
that NUDT15 variant alleles represent a highly robust toxicity-related locus in 
Asian populations (Moriyama et al., 2016; Zgheib et al., 2017; Zhu et al., 2016). 
The risk allele (rs116855232) is most frequent in East Asians (9.8%), followed 
by Hispanics (3.9%); it is exceedingly rare in Europeans (0.2%) and not 
observed in Africans (Yang et al., 2015). More research examining the 
association between NUDT15 genotype and thiopurine intolerance is needed. 
Nevertheless, the results obtained thus far suggest that the NUDT15 risk allele 
should be considered a factor in leucopenia risk for patients undergoing thio-
purine therapy.  
 
 
The MOCOS enzyme sulfurates the molybdenum cofactor of XO and AOX, 
key enzymes involved in the degradation of thiopurines. In a preliminary study 
still in need of independent confirmation, Kurzawski et al. (2012) found that 
the MOCOS rs594445 polymorphism influenced AZA dose responsivity in a 
manner similar to TPMT heterozygosity in a cohort of kidney transplant recipients 
on AZA therapy. Furthermore, recently, Coelho et al. (2016) identified an 
association between the MOCOS gene and TPMT activity. However, the 
mechanism by which MOCOS may influence TPMT function remains to be 
determined.  
 
 
Dysfunction of transport proteins specific for thiopurine metabolites may 
explain some of the variability in thiopurine clinical efficacy and ADRs. It has 
been shown that down-regulation of SLC28 and SLC29, which mediate the 
cellular intake of the nucleosides and nucleoside analogues, decreases the uptake 
of thiopurines and therefore the cellular accumulation of TGNs (Fotoohi et al., 
2006; Zaza et al., 2005).  
1.4.3.8. Nucleoside diphosphate-linked moiety X-type motif 15 (NUD15) 
1.4.3.9. Molybdenum cofactor sulfurase (MOCOS) 
1.4.3.10. Drug transporters 
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ATP binding cassette subfamily C member 4 (ABCC4) is a nucleotide efflux 
transporter for purines that is expressed in many cells, including myeloid 
progenitors. ABCC4 protects cells from the accumulation of cytotoxic meta-
bolites that can modify sensitivity and resistance to thiopurine therapy (Janke et 
al., 2008; Krishnamurthy et al., 2008; Sampath et al., 2002). ABCC4 genetic 
variant that reduces the encoded transporter’s activity dramatically and were 
associated with depressed white blood cell counts were identified in a cohort of 
Japanese patients undergoing thiopurine therapy for IBD (Ban et al., 2010). It is 
not yet known whether this phenomenon generalizes to other populations. 
 
  
1.5. Using TPMT pheno- and genotyping  
to guide thiopurine therapy 
Dosing decisions for specific patients can be informed by a variety of biological 
markers associated with a drug-disease combination, such as genotype, gene 
expression profile, protein/enzyme concentration/activity, systemic metabolite/ 
drug levels, and cell/clinical response (Jayachandran et al., 2015). Pharmaco-
genetic information is included on the labels of more than 180 drugs approved 
by US FDA and European Medicines Agency. Some include dosing guidelines 
based on genetic factors, such as gene variants (including TPMT), functional 
deficiencies, expression changes, and chromosomal abnormalities.1 
There is still ongoing debate as to whether TPMT pheno- or genotyping are 
reliable enough to be used to determine treatment course and whether such 
testing would be cost-effective. In 2016, a large meta-analysis of 47 high-quality 
pharmocogenetic studies, of which 12 involved TPMT testing, yielded mixed 
results for TPMT. The cost-effectiveness of genotyping prior to the use of 6-MP 
or AZA was highly variable across studies, casting doubt on whether such 
testing would be worthwhile (Plumpton et al., 2016). The position of the 
European Crohn’s and Colitis Organization thus far has been that no recommen-
dations can be made according to TPMT geno- and phenotype (Travis et al., 
2006), whereas the American Gastroenterological Association included it in 
their consensus on immunosuppressive therapy (Lichtenstein et al., 2006). 
Regardless, because TPMT is a well-known and important thiopurine meta-
bolizing enzyme, several assays have been developed to measure TMPT activity 
and assess TPMT genotype.  
The first guidelines for thiopurine starting dose for use at therapy initiation 
based on TPMT pheno- and genotype have been established by the Clinical 
Pharmacogenetics Implementation Consortium from the US National Institutes 
of Health (Relling et al., 2013; Relling et al., 2011); the therapeutic algorithm is 
depicted in Figure 9A and B. Current TPMT genotype-based recommendations 
are as follows: wild-type homozygotes, standard AZA dosage (2.5 mg/kg/d); 
                                                                          
1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4490128b-e73f-4849-9d6e-
e8591639d771 
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heterozygotes, 30–70% of standard dosage; mutant homozygotes or compound 
heterozygotes, 10% dosage or switch to alternative drug. For the two latter 
groups, therapeutic monitoring is important to confirm whether the adjusted 
dosage is appropriate (Relling et al., 2013; Relling et al., 2011). Notably, 
because some patients exhibit TPMT geno-/phenotype discrepancies, in vivo 
enzyme activity assays are useful. For patients with IBD who are undergoing 
thiopurine treatment, therapeutic drug monitoring (TDM) based on thiopurine 
metabolite levels (6-TGN or 6-MMP) may enable clinicians to optimize the 
treatment, prevent ADRs, and help elucidate the mechanisms of clinically poor 
response or drug resistance (Moon and Loftus, 2016; Roblin et al., 2011).  
 
 
1.5.1. Measurement of TPMT enzyme activity 
TPMT is widely expressed in the human body with expression varying between 
tissues, with notably high TPMT activity levels in the liver and kidneys, and 
relatively lower activity levels in the brain, lungs, intestine, and placenta (Lee et 
al., 1995). TPMT tissue-specific distribution differs pre- versus postnatally 
(Pacifici et al., 1991). Because hepatic TPMT activity correlates well with that 
in erythrocytes, the phenotypic measurements are usually carried out on whole 
blood owing to the low invasiveness of drawing blood (Szumlanski et al., 1992; 
Van Loon and Weinshilboum, 1982).  
There are several methods available for assessing TPMT status. TPMT 
activity is most commonly determined by measurement of 6-MMP formation 
from 6-MP employing SAM as a methyl donor (Loit et al., 2011). The originally 
developed radiochemical method has been modified over the years to rely on 
nonradioactive detection by high performance liquid chromatography (HPLC) 
(Jacqz-Aigrain et al., 1994; Lennard and Singleton, 1994; Weinshilboum et al., 
1978). A method that uses 6-TG as the enzyme substrate instead of 6-MP has 
also been developed (Kröplin et al., 1998). The choice of dosage threshold 
criteria is crucial and may be influenced by the patient population as well as the 
clinical indication for testing (Roberts et al., 2007; Zur et al., 2016). Although 
TPMT phenotyping provides important information for treatment planning, 
patients’ on thiopurine therapy should be also monitored for toxicity and drug 
metabolite levels because numerous other factors can influence ADR risk, 
including blood transfusions, age, renal function, interactions with other drugs, 
and genetics.  
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Figure 9. A: Before initiating thiopurine therapy, determine recommended starting dose 
based on TPMT pheno-/genotype. During thiopurine treatment, therapeutic monitoring 
is critical for patients on adjusted dosages. *or compound heterozygote. B: TDM based 
on thiopurine metabolite profiles in IBD patients experiencing toxicity or resistance. 
*low/absent TPMT activity (homozygous mutant or compound heterozygote). 
Abbreviations: TPMT, thiopurine methyltransferase; AZA, azathiopurine; 6-MP, 6-mer-
captopurine; 6-TNG, 6-thioguanine nucleotides; 6-MMP(R), 6-methylmercaptopurine 
ribonucleotides. Panel A dapted from (Relling et al., 2011); panel B adapted from 
(Dewit et al., 2010). 
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1.5.2. Diagnostic genotyping of TPMT  
Generally, genotyping in routine clinical laboratories targets specific variants, 
mostly the most common ones. When ethnic background is considered in the 
selection of target alleles, one may identify up to 95% of individuals with the 
clinically relevant alleles. However, rare variants or relevant alleles in other 
genes may still be missed in some cases (Zur et al., 2016). Genotyping methods 
used in practice include restriction-fragment length polymorphism (Coulthard et 
al., 1998; Yates et al., 1997), denaturing HLPC (Hall et al., 2001; Schaeffeler et 
al., 2001), and sequencing (Haglund et al., 2004). The advantage of TPMT geno-
typing over phenotyping is that it never changes, whereas TPMT activity may 
be influenced by several factors. However, the cost-effectiveness of genotyping 
of TPMT remains in question (Plumpton et al., 2016). 
Both genotyping and phenotyping have their limitations. Obviously, pheno-
typing by measuring RBC TPMT activity is misleading in patients who have 
received blood transfusions because it reflects the enzyme activity of donor 
RBCs. On the other hand, we still do not know and understand all of the DNA 
sequence variations that influence TPMT activity. Considering current state of 
knowledge, ideally, both pheno- and genotyping should be used with other 
clinically relevant monitoring applications to guide the best therapy. 
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Epilogue 
Future perspectives of pharmacogenomics  
There is substantial interindividual heterogeneity in drug responses with respect 
to both efficacy and toxicity. The proportion of patients who respond bene-
ficially to the first drug offered in the treatment of a wide range of diseases has 
reported to be 20–60% (Wilkinson, 2005). For example, on average, 38%, 40%, 
43%, 50%, and 75% of patients who have depression, asthma, diabetes, arthritis, 
and cancer, respectively, show no response to their initial treatments (Spear et 
al., 2001). Furthermore, between 1990 and 2013, 43 drugs were withdrawn 
from the market due to severe ADRs (Wei et al., 2012). Approximately 6.5% of 
admissions to hospitals are related to ADRs. Hence, interindividual drug response 
variability is an important factor in morbidity and can lead to potentially 
avoidable strains on limited healthcare resources (Pillans, 2008).  
As the cost of whole-genome sequencing is declining, it has been predicted 
that in the near future, every individual could have their entire genome sequenced 
in early life with the information being available for clinical use throughout 
one’s lifetime. Thus, we are moving forward from the debate over the need for 
introducing PGx markers into the clinic towards a discussion about how to pre-
emptively integrate genetic information into everyday clinical practice. More 
than 180 US FDA-approved drugs have at least one PGx association in their 
product labeling2 and pharmaceutical companies are realizing the need to include 
genomic information in clinical trials.  
Clinical drug responses and outcomes are always patient-specific. Such 
interindividual variation is often a challenge to optimizing dosage. Because 
different patients respond differently to the same drug and dose, the suggested 
population-based standard dose can lead to severe ADRs, including death, in 
some patients or result in therapeutic failure in others. TDM is suggested for 
drugs with a narrow therapeutic index or known serious ADRs (Ahmed et al., 
2016). Many studies have been conducted to identify PGx markers with possible 
effect on diseases or conditions through drug pharmacokinetics/-dynamics. For 
example, several drug metabolizing enzymes, transporters, and receptors have 
been discovered to have potential effect on metabolic pathways of certain anti-
cancer drugs. But for most chemotherapeutics, the association of gene poly-
morphisms with pharmacokinetics is not well understood (Bertholee et al., 
2016).  
Several implementation studies and programs have been initiated in recent 
years to address the barriers that prevent the clinical implementation of PGx. 
The main aims related to overcoming these hurdles are: implementing drug-
gene pairs one at a time and assessing their clinical utility; educating healthcare 
providers on PGx; implementing existing CPIC and Dutch Pharmacogenomic 
Working Group guidelines; integrating PGx test results into the electronic health 
records and clinical decision support systems at the point of care to guide 
                                                                          
2  http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm 
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healthcare providers (including the standardization of pharmacogenetic terms 
for clinical tests); and expanding the field of PGx by making use of next gene-
ration sequencing techniques. Notably, to improve the cost-effectiveness, the 
Ubiquitous Pharmacogenomics Consortium aims to develop a panel of relevant 
PGx markers for various therapeutic areas for pre-emptive clinical testing rather 
than advancing single gene-drug pairs (Caudle et al., 2016; Relling and Evans, 
2015; van der Wouden et al., 2016). 
Analyses of large-scale sequencing efforts, such as the 1000Genomes project 
and Exome Sequencing Project, have indicated that each individual harbors, on 
average, more than 100 SNPs, of which 90% are rare non-synonymous variants 
in pharmacogenetic loci (minor allele frequency < 1%). It was estimated that 
these variants account for 30–40% of the functional variability in so-called 
adsorption-distribution-metabolism-excretion pharmacogenes (Kozyra et al., 
2017). Thus, beyond the potential clinical utility of identifying such variants, 
they may have a major impact on drug discovery, particularly with respect to 
potentially driving stratified drug development. In light of the fact that drug 
development is very complex, time consuming, and costly, it is important to 
recognize that PGx studies enable predictions of drug response to be made 
based on individual variations, identifying patient subgroups that are most likely 
to respond. The information gained is helpful for designing drugs and drug 
therapy regimes based on patient profile (Gupta and Jhawat, 2017).  
Beyond the research identifying the contributions of genetic variants to 
differences in drug response and efficacy, other “-OMICS” are emerging with 
potential applications in PGx. For example, (pharmaco)epigenomics (including 
microRNAs) and (pharmaco)metagenomics may expand the scope of PGx. Both 
are dynamic over time and quite susceptible to environmental factors. There is a 
growing body of evidence indicating that epigenomic alterations, such as methy-
lation, histone modification, and microRNAs, regulate the expression of genes 
involved in drug metabolism, xenobiotic transport, drug target effects, and down-
stream signaling molecules, either directly or indirectly (Ingelman-Sundberg 
and Cascorbi, 2016).  
Recognition of the physiological importance of the microbiome of the 
human gut is growing. Gut microbe genomes encode gene products that extend 
human metabolism biotransform xenobiotics, including drugs, in direct or 
indirect ways. Thus far, already more than 50 drugs have been shown to be 
amenable, in vitro or in vivo, to being metabolized by gut microbiota via bio-
chemical reduction and/or hydrolysis. Understanding the metabolic contributions 
of gut microbes may provide information about the energetic demands of the 
gut microbiota and be useful for predicting how drugs will be modified 
(Spanogiannopoulos et al., 2016).  
Combining PGx with traditional clinical phenotypic variables (e.g., sex and 
age) alone is unlikely to be sufficient to describe the net effect of the multitude of 
factors influencing drug responses adequately. Thus, Turner and colleagues have 
proposed a new interdisciplinary translational field, called systems pharmacology, 
that aims to parse systematically and comprehensively all of a drug’s clinically 
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relevant activities to explain, simulate, and predict clinical drug responsivity. It 
is hoped that systems pharmacology will accelerate drug discovery and develop-
ment by way of facilitating the identification and validation of new targets, 
elucidating target network responses to drug perturbation, and uncovering drug-
response biomarkers. Moreover, the application of systems pharmacology holds 
additional transformative potential for a deeper parsing of interindividual drug 
variability, which would facilitate drug stratification (Turner et al., 2015).  
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AIMS OF THE STUDY 
The overall aim of the thesis was to identify causes of variability in TPMT 
activity in healthy individuals and acute ALL patients.  
 
The specific aims of the studies were as follows: 
1. To identify new markers and haplotypes in the TPMT gene explaining the 
variability in TPMT activity in randomly selected healthy individuals in 
Estonia (Ref. I). 
2. To investigate the influence of SAM on TPMT activity in human subjects 
(Ref. II). 
3. To search for new genetic markers, beyond TPMT, to explain the variability 
in TPMT activity in the general population and among ALL patients using a 
genome-wide approach (Ref. III).  
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MATERIALS AND METHODS 
The population cohort studies in Ref I–III were approved by the Ethics Review 
Committee on Human Research of the University of Tartu, Estonia. The study 
of ALL and IKP (Institut für Klinische Pharmakologie) cohort in Ref III was 
approved by the ethics committees of the Charité, Humboldt University in 
Berlin, Germany and the University of Tübingen in Tübingen, Germany in 
accordance with the principles of the Declaration of Helsinki. Informed consent 
and filled questionnaires were obtained from all study participants. 
 
 
3.1. Study subjects and sample preparation 
First phase (Ref I) 
Estonian population cohort 
Venous blood samples were collected from 253 healthy blood donors (127 
males, 126 females) at the Blood Centre of Tartu University Hospital in Estonia. 
DNA was extracted from whole blood. TPMT activity was measured in hemoly-
sates prepared from RBCs.  
 
Second phase (Ref II) 
Estonian population cohort 
Individuals were recruited from the Estonian Genome Center at the University 
of Tartu in Estonia. The cohort was composed of 1017 healthy individuals (511 
males, 507 females) with a wide range of health statuses and demographic infor-
mation. DNA was extracted from whole blood samples; hemolysates prepared 
from RBCs were subjected to TPMT and SAM measurements. A set of 19 bio-
chemical parameters from plasma and ten hematological parameters from whole 
blood were measured at Tartu University Hospital. 
 
 
 
 
Second phase (Ref III) 
Estonian population cohort 
A portion of the Ref II cohort was recruited (N = 844; 414 males, 430 females). 
 
ALL study cohort  
Children diagnosed with ALL (N = 245) who participated in the Berlin-
Frankfurt-Münster trials were included. None of the patients had been trans-
fused within 3 months prior to blood sampling. The samples were obtained before 
ALL maintenance therapy. Genomic DNA was extracted from whole blood; 
RBC lysates were prepared for TPMT assay. 
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IKP liver cohort  
Histologically normal liver tissues (N = 124) and corresponding blood samples 
(N = 150) were collected from patients undergoing liver surgery at the 
Department of General, Visceral, and Transplantation Surgery, University 
Medical Center Charité in Berlin, Germany. DNA was extracted from whole 
blood; cytosol was prepared for TPMT assay.  
 
 
3.2. Biochemical measurements 
First phase (Ref I) 
TPMT activity was measured in the RBC hemolysates obtained for all 253 
subjects. The samples were submitted to HPLC with UV detection and 6-MP as 
the substrate at the Department of Pharmacology at the University of Tartu in 
Estonia. 
 
Second phase (Ref II) 
TPMT activity and SAM levels were measured in all 1017 RBC hemolysate 
samples by HPLC at the Department of Clinical Biochemistry, University of 
Ljubljana, Slovenia. For the TPMT assay, 6-MP was used as a substrate. 
 
Second phase (Ref III) 
TPMT activity was measured in the RBC hemolysate samples from all three 
cohorts by non-radioactive HPLC with 6-TG as a substrate at the Dr. Margaret 
Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart. 
 
 
3.3. Genotyping and imputation 
3.3.1. TPMT genotyping 
First phase (Ref I) 
The coding region of TPMT was analyzed for 154 subjects, including all 45 
individuals with intermediate TPMT activity, all 19 with high TPMT activity, 
and a sample of 90 individuals with normal enzyme activity. To avoid ampli-
fication of the TPMT processed pseudogene, intron-specific polymerase chain 
reaction (PCR) primers were designed and the PCR primers were used to 
sequence the coding region of the TPMT gene. The program ChromasPro 1.34 
was used for sequence analysis (Technelysium Pty Ltd).  
 
Second phase (Ref II and Ref III) 
The Estonian population cohort was genotyped for TPMT*2, *3B, and *3C 
alleles by TaqMan Genotyping Assays (Applied Biosystems). The ALL and 
IKP-liver cohorts were genotyped for the same alleles by TaqMan Genotyping 
Assays (Applied Biosystems) or matrix-assisted laser-desorption ionization–
time-of-flight mass spectrometry (Sequenom).  
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3.3.2. Whole-genome genotyping 
Second phase (Ref III) 
Genome-wide genotyping for the Estonian population, ALL, and IKP-liver 
cohorts was performed with HumanCNV370, Human Omni1-Quad, and 
HumanHap300 arrays (Illumina, Inc), respectively. After conducting quality 
control, imputation, and filtering, the following markers were included in the 
subsequent association analyses: 8,617,769 markers in 844 Estonian cohort 
samples; 8,224,478 markers in 245 ALL cohort; 7,481,872 markers in 123 IKP-
liver cohort samples.  
 
 
3.3.3. Next-generation sequencing 
Second phase (Ref III) 
In the IKP-liver cohort samples, TPMT was analyzed for the presence of genetic 
variations by targeted exome sequencing in the HiSeq2500 platform (Illumina, 
Inc) at the Center for Genomics and Transcriptomics in Tübingen, Germany.  
 
 
3.4. TPMT mRNA and protein quantification 
Second phase (Ref III) 
TPMT mRNA was quantified with a TaqMan® Gene Expression Assay 
(Hs00909011_m1, Applied Biosystems). TPMT expression was normalized 
against ß-actin measured with a HUMAN ACTB Endogenous Control Assay 
(Applied Biosystems). The measurements were conducted on a Fast Real-time 
PCR System (7900HT, Applied Biosystems). TPMT protein expression was 
quantified by immunoblot analyses of liver cytosol with a specific rabbit anti-
TPMT antibody (Mayo Clinic). TPMT protein levels (available for 122 samples) 
were quantified through immunoblotting.   
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RESULTS 
4.1. Identification of known and new TPMT variants  
in healthy Estonians (Ref. I) 
4.1.1. Distribution of TPMT activity and influence of gender 
Mean (± standard deviation, SD) TPMT activity in 253 healthy Estonians (127 
males, 126 females) was 90.60 ± 32.27 ng/ml/h (range, 21.5–185.5 ng/ml/h). 
Males had a higher mean enzyme activity level (97.07 ± 34.66 ng/ml/h) than 
females (84.18 ± 28.41 ng/ml/h; Mann-Whitney U-test, p = 0.0022). Values in 
the range of 60–140 ng/ml/h were considered normal (arbitrary cut-off values); 
values below and above this range were considered intermediate and high, 
respectively. No subjects had a complete enzyme deficiency. Shapiro-Wilk W-
test indicated a non-normal distribution of the wild-type population as a whole 
(W = 0.98, p < 0.001) as well as of the normal TPMT activity group (W = 0.94, 
p < 0.0001). Based on the aforementioned cut-off criteria, 45 subjects were 
placed in the intermediate, 189 in the normal, and 19 in the high TPMT activity 
groups (Fig. 10).  
 
 
 
4.1.2. Identification of TPMT sequence variants 
After sequencing the coding region of TPMT (exons 3–10) in 154 individuals (45 
intermediate, 19 high, and 90 normal enzyme activity), 16 markers were identi-
fied, of which three were new (Table 2). Five previously known mutant alleles 
were detected: TPMT*2, *3A, *3C, *9 and *12. Subjects who were carrying these 
mutant alleles include 15 TPMT*1/*3A, 2 TPMT*1/*3C, and 2 TPMT*1/*2 
heterozygotes, as well as 1 TPMT*1/*9 and 1 TPMT*1/*12 heterozygote.  
 
 
Figure 10. Distribution of TPMT activity among 253 healthy Estonians. Components of 
the distribution that formed the intermediate, normal, and high enzyme activity groups 
are indicated (graphic legend).  
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The three new mutations were a silent –30T>A mutation in the 5’-untranslated 
region (UTR), a 10A>G mutation in intron 3, and a 145A>G mutation in the  
3’-UTR. All three were present heterozygously. 
 
 
4.1.3. Genotype-phenotype comparison and haplotype analysis 
An association analysis revealed no significant differences in marker frequency 
between the normal and high TPMT activity groups. In the intermediate enzyme 
activity group, four markers [114T>A, 94T>A, 460G>A (*3B), 719A>G (*3C)] 
were found to be in strong linkage disequilibrium (LD), and the frequencies of 
these markers differed significantly from those in the control group (normal and 
high activity groups combined; p < 0.001, Table 2, Fig. 11). 
 
The haplotype analysis yielded two haploblocks. The haplotype frequencies for 
intermediate, normal, and high TPMT activity groups, as determined in 
Haploview, are presented in Table 3. The haplotype analysis further revealed 
that haplotype (H3) from the second haploblock was associated with reduced 
enzyme activity (p < 0.001). None of the haplotypes from the first haploblock 
were associated with TPMT activity. 
 
 
 
 
 
 
 
 
 
 
Figure 11. Comparison of enzyme activity between wild-type (☐) and heterozygous 
() individuals regarding four significant markers. X-axis, enzyme activity (mg/ml/h); 
y-axis, number of individuals. 
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4.2. SAM modulates TPMT activity (Ref. II) 
4.2.1. TPMT activity, SAM levels, and TPMT genotypes 
In this study cohort of 1017 subjects, 828 (81.4%) exhibited normal 
(≥26.1 nmol/g Hb/h; 26.12–102.50 nmol/g Hb/h) and 189 (18.6%) exhibited low 
(<26.1 nmol/g Hb/h; 12.80–26.09 nmol/g Hb/h) TPMT activity. Meanwhile, 
520 subjects (51.1%) had high SAM levels (≥16.6 nmol/g Hb; 16.61–
50.90 nmol/g Hb) and 497 (48.9%) had low SAM levels (<16.6 nmol/g Hb; 
1.60–16.60 nmol/g Hb).  
Genotyping for TPMT*2, *3A, and *3C indicated that of the 1017 subjects, 
961 (94.5%) had the wild-type TPMT genotype (TPMT*1/*1), 50 (5.1%) were 
TPMT*1/*3A heterozygotes, and 6 (0.6%) were TPMT*1/*3C heterozygotes. 
No mutant homozygotes or TPMT*2 alleles were found in the cohort. Of the 
961 TPMT wild-type individuals, 818 (85.1%) had normal and 143 (14.9%) had 
low TPMT activity, respectively. Meanwhile, of the 56 TPMT-heterozygous 
subjects, 46 (82.1%) had low and 10 (17.9%) had normal TPMT activity.  
 
 
4.2.2. In addition to TPMT genotype,  
SAM is a main predictor of the TPMT activity 
The influence of TPMT genotype, SAM levels, and 41 other factors (objective, 
demographic, biochemical, and hematological values) on TPMT activity was 
investigated. Although several factors had an association p-value suggestive of 
influencing TPMT activity (<0.05) initially, after correction for multiple testing, 
only TPMT genotype and SAM levels remained statistically significant 
(p ≤ 1 × 10–13).  
 
 
Table 3. Haplotype frequencies in three TPMT activity groups. 
Block 1 1111A>T 35T>C 58C>T Intermediate Normal High 
H1 T T C 0.575 0.500 0.523 
H2 A C T 0.375 0.446 0.477 
H3 A T C 0.050 0.043 – 
H4 A T T – 0.011 – 
       
Block 2 474T>C 14G>T  Intermediate Normal High 
H1 C G  0.200 0.217 0.205 
H2 T T  0.575 0.766 0.795 
H3 T G  0.225 0.016 – 
H1-H4, haplotypes 1–4 
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4.2.3.  Influence of SAM on TPMT activity is more pronounced  
in TPMT-heterozygous individuals 
The correlation between SAM levels and TPMT activity was much stronger in 
TPMT-heterozygotes (r = 0.651, N = 56) than in wild-type individuals 
(r = 0.252, N = 961). The distribution of TPMT activity across the four TPMT 
genotype/SAM level groups showed the expected pattern, with the highest 
enzyme activity occurring in the TPMT-wild-type–high SAM group and the 
lowest activity being observed in TPMT-heterozygous individuals with low 
SAM levels (Fig. 12), indicating that healthy individuals can be divided into 
four TPMT-phenotype groups on the basis of TPMT genotype and SAM level. 
The influence of SAM on TPMT activity was significant within TPMT 
genotype groups, and was particularly pronounced in TPMT*1/*3 subjects (Fig. 
12).  
 
 
 
Figure 12. Distribution of TPMT activity according to TPMT genotype and SAM 
levels. TPMT activity differed significantly across the four TPMT genotype/SAM level 
combination groups (p = 1 × 10–13). Individuals with the TPMT-wild-type (TPMT*1/*1) 
genotype and high SAM levels had the highest TPMT activity, while heterozygous 
(TPMT*1/*3) individuals with low SAM levels had the lowest TPMT activity. SAM 
levels had a significant influence within the TPMT genotype groups. Error bars show 
95% confidence intervals of the mean values. Dashed line show mean values for each 
TPMT genotype/SAM level group.  
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Next, we looked at the correlation between SAM and TPMT activity in four 
TPMT genotype-phenotype groups shown in Figure 12. The four presently 
observed TPMT genotype-phenotype groups were consistent with clinical 
observations, where the majority of patients belong to two genotype-phenotype 
concordant groups (wild-type genotype with normal activity and heterozygous 
genotype with intermediate activity) and a minority of individuals have 
discordant TPMT genotypes and phenotypes (wild-type genotype with low 
activity or heterozygous genotype with normal activity). This discordance is a 
major obstacle to more extensive implementation of pharmacogenetics in clinical 
practice. In our cohort, the two groups with concordant TPMT genotypes and 
phenotypes had very similar correlation coefficients between TPMT activity 
and SAM (wild-type with normal activity, r = 0.259; heterozygous with inter-
mediate activity, r = 0.299), while the coefficients obtained for the two 
discordant groups differed substantially. In TPMT-wild-type with low TPMT 
activity, TPMT activity did not correlate with SAM levels (r = –0.059). By 
contrast, in TPMT heterozygotes with normal TPMT activity, we observed a 
very strong correlation between the TPMT activity and SAM levels (r = 0.879), 
indicating that the discrepancy between TPMT genotype and activity in indi-
viduals carrying a mutated TPMT allele might be due to differing SAM levels. 
The discovery that unexpectedly high TPMT activity in some TPMT-
heterozygous individuals might be due to higher than typical SAM levels is 
supported by the finding that the difference in the mean SAM levels between 
the genotype–phenotype-concordant and -discordant groups was much more 
pronounced in TPMT*1/*3 heterozygotes than in TPMT-wild-type individuals. 
As illustrated in Figure 13, TPMT-wild-type individuals with low enzyme 
activity had a mean SAM concentration only 2 units lower than TPMT-wild-
type individuals with normal enzyme activity, a difference that is unlikely to be 
clinically significant despite the p-value. On the other hand, among TPMT*1/*3 
subjects, those with normal TPMT activity had a mean SAM level 10.5 units 
higher than those with low enzyme activity, a difference that could be important 
in a clinical setting.  
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Figure 13. Comparisons of SAM levels between normal- and low-TPMT activity 
individuals within two TPMT genotype groups. In both wild-type and heterozygous 
individuals, SAM levels were higher in the group exhibiting normal enzyme activity 
(means, 17.5 nmol/g Hb and 20.7 nmol/g Hb, respectively) than in the groups with low 
TPMT activity levels (15.5 nmol/g Hb and 10.2 nmol/g Hb, respectively). However, the 
difference in SAM levels was greater in TPMT heterozygotes (i.e., 20.7 vs. 10.2 nmol/g 
Hb), indicating that the unexpectedly high TPMT activity in some heterozygous 
individuals might be due to higher SAM levels. Error bars show 95% confidence 
intervals of the mean values. Dashed lines show mean SAM levels for each genotype-
phenotype group. Hb, hemoglobin.  
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4.3. A genome-wide meta-analysis revealed the TPMT locus 
as the main determinant of TPMT phenotype (Ref. III) 
4.3.1. TPMT phenotype-genotype associations in three studied cohorts 
First, we investigated the relationship between genome-wide genotypes and 
TPMT activity in a cohort of Estonians from the general population. TPMT 
activity measured in RBCs showed a bimodal distribution of TPMT activity 
without any cases of TPMT deficiency. The association analysis of TPMT*3 
alleles with TPMT activity showed significantly lower TPMT activity in hetero-
zygotes (median 21, range 13–33 nmol/g Hb/h) than in wild-type homozygotes 
(median 40, range 18–64 nmol/g Hb/h; Fig. 14A).  
Next, we investigated whether the same relationship between genotype and 
TPMT activity exists in pediatric ALL patients. The distribution of TPMT 
activity showed two patients with a profound TPMT deficiency (activity ≤2 
nmol/g Hb/h): one with the TPMT*3A/*11 genotype and one TPMT*3A/*3A 
homozygote. TPMT wild-type carriers had significantly higher TPMT activity 
levels (median 30, range 9–69 nmol/g Hb/h) than heterozygous carriers of 
defective TPMT alleles (median 21, range 9–33 nmol/g Hb/h; Fig. 14B).  
After making these observations, we sought to identify genetic markers that 
influence TPMT activity in the liver, which is composed of the most important 
thiopurine metabolizing tissue in the human body. TPMT activity in liver 
cytosol showed a bimodal distribution and none of the samples were TPMT-
deficient. Liver cytosol samples from carriers of the TPMT*2 and TPMT*3A 
alleles showed reduced hepatic TPMT activity (median 1.2, range 1.1–1.9 
nmol/h/mg) compared to those of wild-type TPMT homozygotes (median 2.7, 
range 1.5–4.1 nmol/h/mg; Fig. 14C).  
 
A                                 B                                             C 
 
 
Figure 14. Association of TPMT activity with wild-type (TPMT*1) and common non-
functional TPMT alleles (TPMT*2, *3A, *3C) in Estonian (A), pediatric ALL (B), and 
IKP liver (C) sample cohorts.  
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4.3.2. Genome-wide association hits in three studied cohorts 
A total of 8,617,769 genotyped and imputed genetic markers in the Estonian 
population cohort (see section 3.3.2) were included in a GWAS for TPMT 
activity, using sex and age as covariates. As shown in a Manhattan plot (Fig. 
15A) and regional association plot (Fig. 15B), the locus showing the most 
significant association with TPMT activity was in the TPMT gene region at 
6p22.3. In total, 169 genetic variants (Table S1 in Ref. III) on chromosome 6 
were significant at the genome-wide threshold (p < 5 × 10–8) with the lowest p-
value being 2.73 × 10–76. 
 
 
 
Figure 15. Results of GWAS for TPMT activity in the Estonian cohort, using age and 
sex as covariates. A. Manhattan plot showing the association p-values of genetic 
variants across chromosomes 1–22. Significantly associated genetic variants, p < 5 × 
10–8, are marked in green. B. Regional association plot highlighting the genomic region 
containing TPMT. Recombination rates and LD estimates (r2) of variants with the TPMT 
variant 719A>G (rs1142345) are displayed. 
 
 
A parallel GWAS of 8,224,478 genotyped and imputed markers in the ALL 
cohort was conducted. As shown in Figure 16, only genetic variants within the 
TPMT gene region were significantly associated with TPMT activity. A list of 
all SNPs that were genome-wide significant (p < 5 × 10–8) is provided in Table 
S2 in Ref. III. The common variant 719A>G (rs1142345), which is present in 
the non-functional TPMT*3A and TPMT*3C alleles, displayed a notably low p-
value.  
Subsequently, we performed a GWAS of 7,481,872 genotyped and imputed 
markers in the IKP-liver cohort, corrected for age and sex, to determine whether 
the association results found in previous cohorts could be further confirmed. As 
shown in Figure 17, only genetic variants within the TPMT region were found 
to be significantly associated with TPMT activity (p < 5 × 10–8) (Table S3, Ref. 
III).  
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Figure 16. Results of GWAS for TPMT activity in the ALL cohort, using age and sex 
as covariates. A. Manhattan plot showing the association p-values of genetic variants 
across chromosomes 1–22. Significantly associated genetic variants, p < 5 × 10–8 are 
marked in green. B. Regional association plot highlighting the genomic region 
containing TPMT. Recombination rates and LD estimates (r2) of variants with the TPMT 
variant 719A>G (rs1142345) are displayed. 
 
Figure 17. Results of GWAS for TPMT activity in IKP human liver samples, using age 
and sex as covariates. A. Manhattan plot showing the association p-values across 
chromosomes 1–22. Significantly associated genetic variants, p < 5 × 10–8 are marked in 
green. B. Regional association plot of these values focusing on the genomic region on 
chromosome 6 (hg19) in which TPMT is located. Recombination rate and LD estimates 
(r2) of variants with the TPMT variant 719A>G (rs1142345) are shown. 
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Further GWAS analyses focused on the most frequent non-functional TPMT 
alleles (TPMT*3A and *3C) were performed in all three cohorts to search for 
genetic factors independent of TPMT. However, no further variants were found 
to be significantly associated (p < 5 × 10–8) with TPMT activity. Moreover, 
previously identified candidate SNPs were not found to be related to TPMT 
activity in the Estonian, ALL, or IKP-liver cohorts in our GWAS results 
(Table 4).  
 
Because systematic data on TPMT expression and in vivo function in the liver 
were not available, we conducted a correlational analysis between cytosolic 
TPMT activity and TPMT protein levels, determined by immunoblotting and 
obtained a highly significant correlation (rs = 0.58, p < 2.2 × 10–16) between 
TPMT’s protein expression level and its enzyme activity level. TPMT mRNA 
expression did not correlate with either TPMT activity or TPMT protein levels 
in the human liver, even after exclusion of TPMT variant cases. These results 
are in accordance with previously published data (Tai et al., 1997) 
 
 
 
 
 
Table 4. Previously implicated SNPs were associated with TPMT activity in the present 
cohorts. 
  
Estonian 
cohort  
ALL  
study  
Liver  
cohort 
gene rs number 
chro-
mo- 
some 
non-
effect 
allele
effect 
allele 
effect 
size 
P- 
value
effect 
size 
P-
value
effect 
size 
P-
value 
PACSIN2§ rs2413739 22 c T 0.06 0.23 –0.07 0.48 –0.02 0.91 
XDH# rs494852 2 C T 0.07 0.36 –0.13 0.26 0.004 0.98 
IMPDH1  rs4731448 7 A G 0.02 0.73 –0.01 0.90 –0.03 0.83 
SLC28A3# rs17428030 9 A G –0.11 0.26 0.04 0.77 –0.30 0.26 
ABCC4# rs17268122 13 G T 0.03 0.62 0.02 0.84 0.15 0.36 
FAM8A6P# rs1040637 6 A G 0.02 0.72 –0.10 0.31 –0.40 0.002 
HIVEP2, 
AIG1# rs200148 6 G A 0.05 0.27 –0.13 0.12 0.13 0.34 
NUDT15* rs554405994 13 – GGAGTC –0.34 0.44 – – – – 
NUDT15* rs186364861 13 G A – – – – – – 
NUDT15* rs116855232 13 C T 0.18 0.61 –0.70 0.20 –0.14 0.87 
NUDT15* rs147390019 13 G A – – –0.55 0.45 – – 
§ (Stocco et al., 2012), # (Matimba et al., 2014), *(Moriyama et al., 2016) 
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4.3.3. Meta-analysis of the studied cohorts 
A joint meta-analysis of all three of the aforementioned datasets was performed 
to increase power and reliability of our GWAS analyses. The meta-GWAS 
revealed significantly associated genetic variants on chromosome 6; among 
them was a sentinel marker of the TPMT gene region (rs73726531, p = 1.2 × 
10–72, effect size: –2.2; Fig. 18A). As shown in the associated regional 
association plot in Figure 18B, this sentinel marker was observed to be tightly 
linked with the TPMT variant 719A>G (rs1142345). Altogether, 148 markers 
on chromosome 6 exceeded the genome-wide significance threshold (p < 5 × 
10–8) in the meta-GWAS (Table S5 in Ref. III).  
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Figure 18. Results of meta-GWAS for TPMT activity of all three cohorts. A. Man-
hattan plot showing the association p-values, revealing significant results only within 
the TPMT locus. The sentinel marker was at chromosome 6:18103028 (rs73726531; 
minor allele frequency = 0.03, p = 1.2 × 10–72; effect size: –2.2), which is linked to 
TPMT variant 719A>G (rs1142345). B. Regional association plot of these values 
focusing on genomic region hg19 in which TPMT is located.  
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5. DISCUSSION 
Ref I was the first study focusing on the distribution of TPMT enzyme activity, 
and the identification and frequency of known and novel sequence variants in 
TPMT in the Estonian population. It is very well known that the frequency of 
mutations that influence drug responses in one population may not be a 
causative variant in another. The variety of TPMT allele patterns that have been 
observed thus far in different ethnic group populations is summarized in 
Table 5. Our finding of higher mean enzyme activity in males than in females is 
consistent with the findings of Schaeffeler et al. (2004), who observed good 
correlations of gender, as well smoking, with enzyme activity. 
 
Table 5. TPMT allele frequencies in different populations. 
Population Allele frequency (%) Reference 
*2 *3A *3B *3C *6 Other alleles 
British 
Caucasian  
(N = 199) 
0.5 4.5 0 0.3 NA NA (Ameyaw et al., 
1999) 
Swedish  
(N = 800) 
0.06 3.75 0.13 0.44 NA NA (Haglund et al., 
2004) 
American 
Caucasian  
(N = 282) 
0.2 3.2 0 0.2 NA NA (Hon et al., 
1999) 
African-
American  
(N = 248) 
0.4 0.8 0 2.4 NA NA (Hon et al., 
1999) 
Ghanaian  
(N = 232) 
0 0 0 6.75 0 3.45 (*8) (Schaeffeler et 
al., 2008) 
Chinese  
(N = 192) 
0 0 0 2.3 NA NA (Collie-Duguid 
et al., 1999) 
Japanese  
(N = 151) 
0 0 0 0.3 NA NA (Kubota and 
Chiba, 2001) 
Russian  
(N = 700) 
0.14 2.6 0 0.36 NA 0 (Nasedkina et 
al., 2006) 
Korean  
(N = 900) 
0 0 0 1.44 0.17 0.07 (*16, *32), 
0.11 (*38) 
(Kim et al., 
2015) 
Estonian  
(N = 253) 
0.4 2.75 0 0.2  0.3 (*9, *12) (Tamm et al., 
2008) 
N, number of individuals; NA, not available.  
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The most frequent TPMT alleles in Caucasians are TPMT*2, *3A and *3C 
(Ameyaw et al., 1999; Haglund et al., 2004; Schaeffeler et al., 2004). Consistent 
with the results obtained in our study, the allele frequencies of TPMT*3A 
among the different populations have been reported to be in the range of 3.2–
5.7%, and those of TPMT*2 and TPMT*3C have been reported to be in the 
range of 0.2–0.8% 3C (Ameyaw et al., 1999; Haglund et al., 2004; Schaeffeler 
et al., 2004). The rest of the TPMT alleles that have been identified to date are 
very rare (i.e., 1 in 300 individuals, Liu et al., 2015; Weinshilboum and Sladek, 
1980). Our study cohort included a single carrier of TPMT*9 and a single 
carrier of TPMT*12, both of whom were heterozygotes. The aforementioned 
variants result in reduced TPMT enzyme activity, as was confirmed by our 
findings of substantially lower TPMT activity levels for heterozygous indi-
viduals (48.8 ± 11.3 ng/ml/h) than for wild-types (93.3 ± 31 ng/ml/h, p < 0.001). 
Three new mutations were identified, including an intronic SNP (10A>G, 
rs20152942), a SNP in the 3’UTR (–30T>A, rs376768623), and a SNP in the 
5’UTR (145A>G). The effects of these mutations on enzyme activity are 
unknown. Given that the rs376768623 allele was paired with the known low-
activity allele TPMT*3A and the carrier had intermediate (some preserved) 
activity, the rs376768623 allele may have no or only a negligible effect on 
enzyme activity. All three of these new mutations are extremely rare, with prior 
examples of only two of them (rs376768623, rs201529425) in very few 
individuals being included in the dbSNP database. The intronic mutations 
114T>A and 94T>A were relatively common in our intermediate TPMT activity 
group. However, additional studies will be necessary to understand if these have 
any regulatory impact on enzyme activity. 
Although genetic variants were found in association with intermediate 
TPMT activity, the present results cannot explain high (or ultra-high) TPMT 
activity. Similar to Dewit et al. (2010), we observed few individuals with ultra-
high TPMT activity. Notably, the TPMT activity in one subject who was 
heterozygous for the extremely rare 399C>T variant was found to be almost 
double the median activity level of the wild-type individuals. This variant allele 
may have a gain-of-function effect, but no final conclusion can be made based 
on data from our single subject nor data in the dbSNP. To date, published 
analyses have not associated any variations in the TPMT open reading frame 
region with ultra-high enzyme activity. However, Roberts et al. (2008) reported 
a triple repeat in the promoter region of TPMT that was associated with very-
high TPMT enzyme activity. We also contributed samples to that work, but the 
effect appeared to be quite specific for individuals of British origin. An alter-
native explanation for heightened TPMT activity may be gene duplication or 
enzyme induction. For example, ultrahigh CYP2D6 enzyme activity has been 
attributed to a functional gene duplication (Dalén et al., 1998). We have 
contributed samples to other studies looking for TPMT gene duplication, but 
none of the studies have yielded positive results. In addition, previous studies 
examining the effect of VNTRs in TPMT promoter region on enzyme activity 
have produced contradictory results (Arenas et al., 2004; Marinaki et al., 2003; 
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Zukic et al., 2010). Finally, it has been established that epigenetic patterns 
affect adsorption-distribution-metabolism-excretion gene expression (Kacevska 
et al., 2012), but no such studies in the literature have included data related to 
TPMT as of yet. 
Our analysis of common markers shared by study participants, regardless of 
their enzyme activity, revealed that several markers formed two haploblocks 
(Table 3). The most interesting result obtained from this analysis was that 
although the markers 474T>C and 14G>T did not associate independently with 
intermediate enzyme activity, their haplotype (H3) may predict reduced TPMT 
activity because it was more frequently present in the intermediate TPMT 
activity group (Table 3). We used the D’ confidence interval algorithm (Gabriel 
et al., 2002) for block definition in Haploview because that haplotype frame-
work provides substantial statistical power in association studies of common 
genetic variation within regions. 
One must consider the fact that TPMT represents only one part of a 
complicated network of biochemical pathways involved in drug metabolism. 
Accordingly, thiopurine drug toxicity has been associated with other genes 
described in this thesis, which contribute to the metabolism of thiopurine drugs 
and may influence TPMT activity directly or indirectly via other factors.  
Even though the correlation between TPMT genotype and thiopurine therapy 
response is good in most cases, an increasing number of patients whose therapy 
responses cannot be predicted on the basis of TPMT genotype alone are being 
seen in clinical practice (Hindorf and Appell, 2012; van Egmond et al., 2012). 
Therefore, the identification of additional (genetic or non-genetic) biomarkers 
of thiopurine response profile is of great importance.  
Studies performed in various experimental paradigms – including an in vitro 
protein model (Scheuermann et al., 2004), cell lines (Milek et al., 2009; Milek 
et al., 2012), and indirect studies of human subjects (Arenas et al., 2005; 
Dorababu et al., 2012; Karas-Kuzelicki et al., 2009) – have shown that SAM 
may modulate TPMT activity as a non-genetic cofactor. Arenas et al. (2005) 
suggested that some cases of patients with a homozygous TPMT-wild-type 
genotype exhibiting low TPMT activity might be explained by the presence of 
the MTHFR 677 TT genotype. More than a decade ago, they hypothesized that 
their result might be due to the fact that MTHFR is a key enzyme in SAM 
biosynthesis, but a direct correlation between SAM and TPMT activity had not 
been reported. Since that time, cell biology studies have demonstrated SAM-
mediated stabilization of TPMT via a posttranslational mechanism that occurs 
in both tumor-derived transformed and primary cells (Milek et al., 2012). 
In our study (Ref II) – which is to our knowledge the first to study the direct 
influence of SAM on TPMT activity in a large number of individuals – we 
showed that SAM is an important modulator of TPMT activity in healthy 
individuals not exposed to thiopurine drugs. More specifically, SAM had a 
greater influence on TPMT activity in TPMT*1/*3 than TPMT-wild-type 
genotype individuals (Fig. 13). This finding is in concordance with the findings 
of Tai et al. (1997) indicating that stabilization of the TPMT protein by SAM is 
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especially pronounced in the presence of mutant TPMT. Our results do not lead 
to the conclusion that SAM levels can explain discrepancies in TPMT activity 
and thiopurine drug responses among wild-type individuals. However, our 
results do support the notion that SAM levels could be an important factor 
modulating TPMT activity in TPMT heterozygotes. Notwithstanding, these data 
should be interpreted with caution due to the small number of subjects in the 
normal activity–heterozygous group. Although this discordant group represents 
only approximately 1% of the population (according to both the present study 
and that conducted by Hindorf and Appell, 2012), in terms of clinical practice, 
this finding means that every fifth to tenth heterozygote may be at increased risk 
of ineffective therapy and relapse if classified only by genotype. Given the 
fairly weak correlations between SAM and TPMT activity in some TPMT 
genotype–phenotype groups, we believe that there are additional modulators of 
TPMT activity that have yet to be identified.  
It should be kept in mind that even though good correlations were obtained 
with TPMT activity data obtained for RBCs and liver cytosol, these measure-
ments are only an approximation of thiopurine-relevant metabolic processes that 
take place mostly in the liver and the various modulators/cofactors of drug 
metabolism may not be represented in RBCs. Duley and Florin (2005) pointed 
out that diagnostic values for TPMT activity and TGN levels are a RBC pheno-
menon poorly equated to the liver, which is the major site of drug methylation. 
Thus, some cases of thiopurine-induced leukopenia cannot be explained by 
RBC TPMT activity or TGN levels, and some individuals with low TPMT 
activity in RBCs can tolerate normal doses of the drug.  
It is also important to note that the present study was conducted in 
individuals who were not undergoing thiopurine therapy. Therefore, prospective 
studies on thiopurine-treated ALL and IBD patients are necessary to evaluate 
the clinical usefulness of determining SAM levels as a predictive factor of thio-
purine therapy response. Diagnostically and economically, it may be reasonable 
to measure SAM levels only in TPMT-mutated patients because such patients, 
when confirmed to have high SAM levels, should be able to tolerate standard 
doses of 6-MP, and thereby experience better therapeutic efficacy than they 
would with a reduced dose. Meanwhile, in TPMT-mutated patients with low 
SAM levels, SAM supplementation during 6-MP therapy could lower the 
incidence of adverse effects. Currently, there is no clinical evidence base for 
SAM supplementation during thiopurine therapy. Thus, further studies in patients 
receiving thiopurines are warranted in the near future.  
The possibility that human microbiota may play an important role in drug 
response in terms of efficacy and ADRs has been gaining attention recently 
(Spanogiannopoulos et al., 2016). In the case of TPMT, which is highly 
evolutionarily conserved, bacterial TPMT reacts with AZA. Moreover, bacterial 
TPMT confers resistance to the bactericidal drug tellurite, highlighting how 
bacterial enzymes can act promiscuously on drugs used to treat humans. Such 
unplanned actions may inactivate a drug before it reaches the intended target 
tissue (Nayak and Turnbaugh, 2016; REMY, 1963).  
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As mentioned earlier in this discussion, concerns remain with regard to 
whether TPMT genetics determine exclusively the substantial inter-individual 
variability of TPMT activity measured in RBCs, or whether other genes may 
contribute substantially. Clinically, it is well-known that in addition to TPMT 
heterozygous individuals, patients with a homozygous wild-type TPMT geno-
type are at risk for thiopurine-related hematotoxicity. Although non-genetic 
factors (like SAM) may underlie thiopurine-related hematotoxicity, the 
mechanisms are not yet well understood as discussed extensively in literature 
overview of this thesis. 
Our meta-analysis (Ref. III) results indicate that TPMT genetics have a 
fundamental impact on TPMT activity (Fig. 18) in humans and provide little 
support for the proposal that other genes may significantly contribute to the 
inter-individual variability of TPMT activity. In addition to investigating blood 
samples from healthy and diseased human cohorts, we also investigated, for the 
first time, human liver samples and the results revealed that only variants on 
chromosome 6 (TPMT region) were significantly associated with TPMT activity 
(Fig. 17). Noticeably, the genome-wide significant hits for TPMT activity were 
found to extend to other genes (e.g. KDM1B) near TPMT. As shown in the 
regional association plot of the meta-GWAS (Fig. 18B), these variants were 
linked with the presence of non-functional TPMT*3 alleles. Further analyses 
conditioned on the TPMT*3A and *3C alleles revealed no variants that were 
significantly associated with TPMT activity in all three cohorts. 
Of note, we observed TPMT genotype-phenotype discordance in ALL 
patients, compared with the Estonian general population cohort. That discordance 
was attributed to the ALL disease process and anemia of patients resulting in 
lower TPMT activities in RBCs due to degraded TPMT enzyme. 
We attempted to replicate effects associated with non-TPMT related 
candidate genes previously identified by a genome-wide study approach with 
HapMapCEU lymphoblastoid cell lines (LCLs) (Matimba et al., 2014; Stocco et 
al., 2012). Of note, LCL, including non-HapMap LCLs, have been promoted as 
useful model systems for cellular pharmacology, biochemistry, and enzymatic 
reaction studies (Zhang and Dolan, 2009). Matimba et al. (2014) proposed a 
minor association (p > 5 × 10-4) between SNPs within “thiopurine-related” 
genes (XDH, IMPDH1, SLC28A3, ABCC4) and “non-thiopurine pathway” 
SNPs (FAM8A6P, AJG1/HIVEP2) with thiopurine cytotoxicity in LCLs, with 
further validation in pediatric ALL patients. Additionally, using a genome-wide 
approach, Liu et al. (2016) sought to identify novel predictors of TPMT activity 
in LCLs and found 96 genes that ranked higher than TPMT itself. With the 
exception of SLC22A16, none of those genes were located on chromosome 6. 
However, our findings provide little support for any such effect being mediated 
through TPMT directly because there was only negligible correlation with 
respect to TPMT activity in our cohorts (Table 4). Noticeably, we did not find 
any variants of SLC22A16 that were significantly associated with TPMT 
activity. Thus, use of LCLs in studies aimed at discovering novel pharma-
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cogenetic loci may have serious limitations. Regardless, validation of results 
obtained in LCLs require validation in large-scale population/patient cohorts.  
SNPs localizing to PACSIN2, a gene previously reported to influence TPMT 
activity and to be related to MP-related gastrointestinal toxicity (Stocco et al., 
2012), were not associated with TPMT activity in our analyses (Table 4). Our 
negative finding in this regard is consistent with the work of Roberts et al. 
(2014b), who failed to confirm an association between PACSIN2 genotype and 
thiopurine-related ADRs in IBD patients.  
Yang et al. (2014) reported that a NUDT15 variant was associated with 
thiopurine-induced leukopenia firstly in a retrospective cohort of Korean IBD 
patients, and that finding was confirmed in subsequent studies involving children 
with ALL and MP intolerance (Tanaka et al., 2015; Yang et al., 2015). Very 
recently, Moriyama et al. (2016) provided mechanistic evidence of how 
NUDT15 variants may alter levels of active thiopurine metabolites, independent 
from TPMT, in a manner that increases thiopurine cytotoxicity. However, we 
did not observe any potential interaction of the NUDT15 R139C variant 
(rs116855232) with TPMT activity in our three cohorts (Table 4). However, it 
should be noted that the frequency of this allele is extremely low in non-Asians, 
including Estonians.  
Although the liver is the predominant site of thiopurine metabolism in 
humans, data demonstrating a close correlation between hepatic TPMT protein 
expression and cytosolic TPMT enzyme activity have been lacking. Here, we 
provide the first available systematic data on TPMT expression (mRNA, 
protein) and function (activity levels) in human liver samples. TPMT mRNA 
was not significantly correlated with either TPMT activity or TPMT protein 
levels, which supports previous findings demonstrating that the common TPMT 
polymorphisms 460G>A and 719A>G affect TPMT activity by way of post-
translational modifications and increased protein degradation (for review see 
Moon and Loftus, 2016). Moreover, TPMT mRNA expression did not correlate 
with either TPMT activity or TPMT protein expression (in immunoblots) in 
subjects carrying the TPMT reference sequence (confirmed by next generation 
sequencing). These data are in contrast to prior results showing a significant 
correlation between normal/high TPMT enzyme activity in RBCs and TPMT 
mRNA levels extracted from whole blood samples taken from 29 individuals 
(Lindqvist et al., 2003). It remains questionable whether the relationship 
between white blood cell mRNA and RBC TPMT enzyme activity is relevant 
for drug metabolism.  
The main limitations of our work are that this study was designed based on 
SNP array data and did not investigate gene duplications/deletions or genomic 
rearrangements, which might alter TPMT activity. Additionally, we did not 
investigate epigenetic regulation of TPMT expression (e.g. by non-coding RNAs 
such as microRNAs), which may be a plausible explanation, at least in part, for 
the lack of reliable correlation between TPMT mRNA expression and TPMT 
protein levels in the liver. Finally, the present study was not designed to identify 
genetic variants associated with thiopurine-related toxicity. Thus, we cannot 
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exclude the possibility that genes beyond TPMT are involved in determining 
thiopurine toxicity risk or treatment outcome.  
The identification of novel rare variant alleles beyond TPMT that are 
associated with TPMT activity will require whole genome next-generation 
sequencing approaches. Our meta-GWAS of data from a combined cohort of 
1212 subjects did not reveal any novel factors that were significantly associated 
with TPMT activity. Notably, we did not find confirmation of previously 
reported associations with other genes besides TPMT. Additional studies are 
needed to test whether such prior associations can be replicated. Moreover, in-
depth research studies are needed to clarify the extent to which and the 
mechanisms through which the present findings may explain the inter-individual 
variability seen in TPMT activity.  
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6. CONCLUSIONS 
This thesis provides an overview of different layers of -omics studies exploring 
inter-individual variability in TPMT activity.  
The following conclusions can be drawn from this dissertation: 
1. None of the newly detected markers in TPMT could be used to explain the 
discrepancies seen in TPMT genotype-phenotype correlations; the causes of 
ultra-high TPMT activity remain to be discovered.  
2. We identified a new pharmacometabolomic marker and therapeutic agent. Of 
the 43 biomarkers tested, only TPMT genotype and RBC SAM levels were 
found to influence TPMT activity significantly. The influence of SAM 
levels on TPMT activity was particularly pronounced in TPMT-hetero-
zygotes. 
3. Our studies did not reveal any additional genetic markers outside of TPMT 
that were predictive of TPMT activity. Although our data confirm that 
TPMT genotype is a robust predictor of TPMT activity in most individuals, 
TPMT genotype alone is insufficient to predict TPMT activity reliably. 
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SUMMARY IN ESTONIAN 
Uute tiopuriinmetüültransferaasi aktiivsust mõjutavate  
biomarkerite otsingul 
Alates inimese genoomi (peaaegu) lõpliku nukleotiidse järjestuse avaldamisest 
16 aastat tagasi, uute ja suure läbilaskevõimega järjestus- ehk sekveneerimis-
tehnoloogiate arengu ning sellega kaasnevate suurte andmemahtudega, mis 
sisaldavad informatsiooni individuaalsete genoomide varieeruvuse kohta, on 
personaalmeditsiin saanud peamiseks suunaks inimesegenoomikas. Selle kõige 
olulisem eesmärk on uute ja usaldusväärsete komplekstunnuseid mõjutavate 
leidude juurutamine kliinilisse praktikasse kasutades inimeste genoomiprofiile 
haigusriskide ja ravimivastuse hindamiseks. Farmakogeneetika/-genoomika on 
selle protsessi üks olulisi harusid, mille abil on võimalik muuta raviotsuste 
tegemine täpsemaks määrates igale patsiendile sobivaima ravimi või ravimi-
doosi, arvestades tema individuaalseid geneetilisi eripärasid.  
Üheks oluliseks võtmeteguriks personaliseeritud kasvajate ja immuunhai-
guste ravis on ensüüm tiopuriinmetüültransferaas (TPMT), mis asub raku tsüto-
plasmas. Kuna TPMT rakusisest substraati ei ole veel tuvastatud, käsitletakse 
seda kui faas II ravimimetaboliseerijat, mis vahendab metüülrühma ülekannet 
S-adenosüül-metioniinilt aromaatsetele ja heterotsüklilistele väävliühenditele. 
Nende väävliühendite hulka kuuluvad ka tiopuriinravimid: 6-merkaptopuriin, 
asatiopriin, 6-tioguaniin, mis metülatsiooni tulemusel inaktiveeruvad. Tiopuriin-
ravimeid kasutatakse tänapäeval peamiselt lapseea leukeemia, autoimmuun-
haiguste ravis ning siirdamisjärgse äratõukereaktsiooni vältimiseks. Suures osas 
sõltub TPMT aktiivsusest eelnimetatud ravimite poolt põhjustatud kõrval-
toimete teke. TPMT madala aktiivsuse tõttu tekib indiviididel tiopuriinide 
standarddooside kasutamisel nn ravimimürgistus. Mitmed uuringud on näidanud, 
et TPMT aktiivsus on pöördvõrdelises seoses tsütotoksiliste metaboliitide 
(tioguaniinnukleotiidide) moodustumisega ja kõrvaltoimete esinemisega st, 
mida madalam on ensüümi aktiivsus, seda kõrgem on tioguaniinnukleotiidide 
tase organismis ja vastupidi. 
Populatsiooniuuringutest on selgunud, et TPMT aktiivsus on kirjeldatav tri-
modaalse jaotusmudeli järgi. Valge rassi hulgas läbiviidud uuringud on näida-
nud, et keskmiselt omab ~0,3% indiviididest väga madalat ensüümi aktiivsust, 
ligikaudu 11% on ensüümi aktiivsus osaliselt vähenenud ja 89% on ensüümi 
aktiivsus normaalne. Seega teoreetiliselt on umbes 11% patsientidest ohustatud 
kõrvaltoimete tekkest eelnimetatud ravimite standarddooside kasutamisel. 
Samas on erinevates populatsiooniuuringutes välja joonistunud grupp indiviide, 
kes omavad tavapärasest kõrgemat ensüümi aktiivsust, kuid siiani ei ole leitud 
selle geneetilisi põhjuseid. Mutatsioonid/SNP-d TPMT geenis võivad mõjutada, 
peamiselt vähendades, ensüümi aktiivsust ning seega kutsuda esile kõrval-
toimeid, eelkõige vereloome pärssumist, ravimite standarddooside kasutamisel. 
Samas tavapärasest kõrgema ensüümi aktiivsusega indiviidide ravimine 
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standarddoosidega ei anna soovitud ravitulemust, kuna ravim metaboliseeri-
takse organismis väga kiiresti.  
Hoolimata mitmetest TPMT ensüümi aktiivsust vähendavate TPMT geeni-
variantide avastamisest, on kliinilises praktikas suureks probleemiks TPMT 
genotüügi-fenotüübi erinevused, eriti nn keskmise ensüümi aktiivsusega indi-
viidide seas. See tähendab, et genotüübi ehk TPMT geenivariantide abil ei ole 
võimalik ensüümi aktiivsust õigesti hinnata. On näidatud, et normaalse (wild-
type) TPMT genotüübiga indiviidide seas esineb madalama ensüümiaktiiv-
susega patsiente ja vastupidi, mis tähendab, et tekivad kõrvaltoimed ravimite 
standarddooside kasutamisel või puudub loodetud raviefekt. See fakt annab 
alust uute geneetiliste ja mitte-geneetiliste biomarkerite otsimiseks, et muuta 
geneetilise info kasutamise kliinilises praktikas täpsemaks ja usaldusväärse-
maks. 
Käesoleva töö kirjanduse ülevaates antakse põhjalik ülevaade farmakoge-
noomikast ja selle erinevatest olulistest komponentidest ning samuti aspektidest, 
mis mõjutavad selle kliinilist juurutamist. Lisaks on iseloomustatud TPMT ja 
tiopuriinravimite metabolismiradu, TPMT aktiivsust mõjutavaid teadaolevaid 
geneetilisi variante ning ka uusi avastatud potentsiaalseid biomarkereid. 
Töö eksperimentaalosa on jagatud kahte etappi. Esimene hõlmab esma-
kordselt eestlaste kohordis (n=253) läbiviidud TPMT genotüübi-fenotüübi 
uuringut. Selle raames sekveneerisime TPMT geeni ning tuvastasime teada-
olevaid ja uusi variatsioone. Leidsime, et eestlastel esineb ka kõige rohkem 
TPMT*3A alleeli heterosügootsust, mis on kooskõlas teiste valge rassi uurin-
gutega. Lisaks avastasime kolm uut geenimuutust, kuid nende mõju ensüümi 
aktiivsusele ei ole teada. Samas ei tuvastanud me ühtegi geenivarianti, mida 
võiks seostada väga kõrge TPMT ensüümi aktiivsusega. Haplotüüpide analüüs 
näitas ühe haplotüübi üleesindatust keskmise ensüümi aktiivsusega indiviidide 
hulgas, kuid antud leid vajab edasisi uuringuid.  
Töö teine etapp keskendub mitte-geneetiliste ja uute geneetiliste biomarke-
rite otsingutele. Kõigepealt uurisime suuremas eestlaste kohordis (n=1017) 
mittegeneetilise faktori S-adenosüül-metioniini (SAM) mõju TPMT aktiiv-
susele. Kuna varasematest töödest on teada, et SAM on TPMTle metüülrühma 
doonoriks ning in vitro katsed on näidanud selle varieeruva taseme mõju ensüümi 
aktiivsusele. Meie eesmärk oli näidata tervete inimeste kohordis, et SAMi 
varieeruv tase on seotud TPMT ensüümi aktiivsuse muutustega. Uuringu tule-
mused kinnitasid, et lisaks TPMT genotüübile on teine oluline ensüümiaktiivuse 
mõjutaja SAM ja seda just mutantse alleeli suhtes heterosügootsete, kuid TPMT 
normaalse aktiivsusega indiviidide seas. Samas, enne uue näitaja kliinilisse 
kasutusse rakendamist, tuleb saadud tulemusi kinnitada suuremas uuringus, 
kuna käesolevas töös kuulus sellisse gruppi (heterosügootne genotüüp-nor-
maalne ensüümi aktiivsus) vaid 10 indiviidi ning samuti ei ole selge tuvastatud 
seos tiopuriine manustavatel patsientidel.  
Seejärel viisime läbi suure assotsiatsiooniuuringu (n=1212) leidmaks uusi 
geneetilisi biomarkereid lisaks TPMT geenile, mis võiksid seletada suurt TPMT 
ensüümi aktiivsuse varieeruvust. Uuringusse kaasati tervete eestlaste (n=844) 
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ning saksa päritolu ägeda lapseea leukeemia patsientide kohort (n=245) ja 
maksaproovid (n=123), mis on peamine ravimimetabolismi kude. Assotsiat-
sioonianalüüsi ja meta-analüüsi tulemused näitasid, et ainult TPMT geeni 
variandid olid seotud TPMT ensüümiaktiivsuse varieeruvusega. Samas ei kinni-
tanud me oma töös varem avaldatud uuringute leide. 
Kokkuvõttes näitavad tulemused, et me tuvastasime uue mitte-geneetilise 
biomarkeri, mille edasised kinnitavad uuringud on väga olulised, selle integ-
reerimiseks kliinilisse kasutusse. Samas me ei leidnud uusi ja ei kinnitanud 
teaduskirjanduses varem avaldatud geneetiliste markerite seost TPMT ensüümi 
aktiivsusega. Kuna tulemused on ebaselged, siis kindlasti ei ole võimalik kliini-
lises igapäevapraktikas kasutada ainult TPMT genotüüpi ensüümiaktiivsuse ja 
ravimivastuse ennustamiseks. Hoolimata juhtnööridest geneetiliste markerite 
kasutamise ja tulemuste tõlgendamise kohta arstide igapäevatöös, tuleb väga 
täpselt jälgida patsiendi ravikulgu kasutades siiamaani kaustuses olevaid 
meetodeid ja raviskeeme. 
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